POPULARITY
2 episodes with gw pharmaceuticals
4 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
8 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
2 episodes with gw pharmaceuticals
Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) co-founder and CEO Melissa Sturgess talked with Proactive's Stephen Gunnion about the company's progress towards beginning its first clinical trial in Australia for its cannabinoid-based drug candidate. Sturgess confirmed that the drug development stage is now complete, allowing the company to move into trials involving healthy volunteers. The trial will compare the pharmacokinetic profile of with the only CBD drug currently approved by regulators. Sturgess discussed the recent appointments of Giles Moss and Chris Tovey—both former senior executives at GW Pharmaceuticals—as strategic moves to strengthen Ananda's commercial and regulatory capabilities as it enters the clinical phase. The Australian Therapeutic Goods Administration has acknowledged Ananda's first trial. Sturgess noted that Australia offers both strong tax incentives and compatibility with US FDA requirements, helping the company advance its program cost-effectively while also preparing for potential regulatory pathways in the United States. Each step forward, Sturgess said, brings Ananda closer to dosing its first volunteers in what she described as a critical phase of development. For more updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #AnandaPharma #CBDClinicalTrial #MelissaSturgess #CannabinoidResearch #PharmaNews #BiotechUpdate #DrugDevelopment #AustraliaTrials #FDAPathway
Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He's going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company's therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It's very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors
Today, we welcome Ryan Lee, Plant breeder, scientist, and 25-year friend of David Watson, aka Sam the Skunkman. Ryan and I connect while he is in Amsterdam helping the family. The conversation explores the legendary life of a cannabis silverback and hero. Sam the Skunkman lived 15 years in Santa Cruz, down the road from the Haze brothers, and is responsible for providing the foundation to all the seed banks in Amsterdam. His life's work is behind modern cannabis medicines from GW Pharmaceuticals. Ryan, who has also done amazing work in the cannabis genome, research, and industry, takes us on a fantastic voyage of a truly epic individual who was like a Forest Gump of sorts in Cannabis. David Watson lived every day to wake up and be happy, learn something new about cannabis, or teach and make some mischief.
Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk. During our conversation, we discuss: What is CHS and who does it affect Why cases of CHS appear to be on the rise Possible genetic markers that could indicate CHS susceptibility Steps cannabis users can take to prevent developing CHS Why some people in the cannabis community don't believe CHS is a real thing and more Thanks to This Episode's Sponsor: Cannabis Nurses Network Established in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community. Learn more at cannabisnursesnetwork.com Additional Resources what-is-chs.com ethanrusso.org CReDO-science.com Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome - CannMed 2019 Panel Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive
Episode 135 of The Simpa Life Podcast features Cefyn Jones the founder of UK-based cannabis consultancy agency Hemp Hound, the host of Hemp Hound TV, and our unofficial CBD/Novel foods specialist correspondent. Links: The Medicalisation of Cannabis document - Irish Committee update - Albanian Fiscal Amnesty - Albert Pike Letter - ACMD Report Previous appearances on The Simpa Life Podcast: - Ep 80- Ep 90 - Ep 116 If you enjoyed this podcast, please consider liking, rating, and subscribing, and if you loved it, also consider becoming a Patreon Check out TheSimpaLife.com for more content and exclusive blogs and articles. You can also follow The Simpa Life on Social media on Twitter Facebook Instagram The Simpa Life Podcast -"Raw and authentic conversations about cannabis, drug law reform, and human rights with weekly guests from around the world” #CefynJones #HempHound #TheSimpaLifePodcast
A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca
Mary and Stefan Nunn unravel his journey from aspiring veterinarian to Legal Counsel at TravelPerk, highlighting the transformative power of legal operations, the innovative role of AI in the field, and the importance of entrepreneurial education and networking beyond the legal re From Vet Dreams to Legal Themes: A quirky leap from aspiring veterinarian to the legal counsel realm. Obstacles in the Legal Lane: The hurdles and exhilarating transition to legal operations. GW Pharmaceuticals and Self-Funding: Tales of contract administration and a self-funded legal practice course. Legal Ops - The Magic Wand: The transformative power of legal operations: think efficiency and standardization. TravelPerk - More than Just Travel: A deep dive into TravelPerk's tech-driven, efficient ethos where the legal team enables. AI in Legal? Heck Yes!: Generative AI's revolutionary impact on law and TravelPerk's tech-forward strategies. Education 2.0: A call for tech-savvy, entrepreneurial legal education. Stepping into Legal Ops: Golden advice: tribe-finding, mentor-seeking, and wide networking. Beyond Law: The potency of connections outside the legal bubble. The Future of Law: Reflecting on the profession's trajectory and the indispensability of business acumen. Stay Connected & Spread the Love: Mary's LinkedIn: Follow Here Ironclad's Socials: LinkedIn YouTube TikTok Show Some Love: Rate & Review on Apple Grab your headphones and dive in. Legal's never been this lively.
A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca
What's wrong with the cannabis industry?Joining us again on the latest episode of The Cannabis Conversation is Dr Ethan Russo, Founder of Credo Science - a novel medical science company.We discuss the prejudice and ignorance against Cannabis, as well as safety monitoring, legalisation and some of the challenges the industry is facing, including a lack of proper funded research in the area.The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at www.luminorecruit.com/About Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com He is also Medical Director of Andira Pharmaceuticals Andira – Bringing Healing to Life and Senior Medical Advisor to Canurta Home | CanurtaPreviously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/
Dr. Ethan Russo and Nishi Whiteley have worked together for almost 10 years in efforts to:improve the scientific understanding of the endocannabinoid system (ECS) and how the cannabis plant modulates itassist small and large cannabis companies in product formulationadvise companies on cannabis genetics enhancementsconsult on pre-clinical and clinical research design.“We share a vision of making cannabis better and safer believing in a future in which knowledge of the endocannabinoid system and its therapeutic modulation via the cannabis plant will result in superior highly individualized medicines, aids to wellness, enhanced lifestyles, and novel non-toxic industrial products”.Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CannabisResearch.org. Previously, he was Director of Research and Development at the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system, and from 2003-2014, he served as Senior Medical Advisor, medical monitor, and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.Nishi Whiteley (pronounced Nee-sha), is the co-founder and Chief Operating Officer at CReDO. She has twenty-five-plus years of international business development experience in cannabis, agriculture, wellness, green energy, and food industries. She has had leadership roles on projects in corporate America and for the US Foreign Ag Service in over 10 countries, in startups, a state agency, and non-profits; as well as worked for foreign governments and met with international leaders in Cuba, Mexico, and the Dominican Republic to open trade and advance development programs. She has worked on investment projects in 8 countries.
LJ Amaral is a Clinical and Research Dietitian specializing in Oncology at Cedars-Sinai Hospital in Los Angeles. She is currently doing research on the ketogenic diet as an adjunct treatment to the standard of care for brain cancer patients. Find LJ at https://www.ljamaral.com Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. - - - In this live salon from 9/20/22 on Clubhouse, Ethan, Dr. Russo and LJ discuss the current research and opportunities presented for brain cancer patients when it comes to diet and nutrition, specifically the Ketogenic Diet and the use of cannabis to treat brain cancer. This conversation was hosted with the support of xCures, learn more and signup for their xINFORM platform that pairs patients with clinical trials at www.xcures.com/brain Learn more about LIFECHANGES at www.ourlifechanges.co and the Love Extremist Project at www.extremist.love
Here is our interview with Dr Callie Seaman. Monkey and Macky sit down with Callie to talk about the state of UK cannabis law, her work with GW Pharmaceuticals and much more. It was a real laid back friendly conversation and I hope you all enjoy it. You can find out more about Dr Seaman over on Facebook, Twitter and Instagram, just search "Dr Callie Seaman". Thanks as always for downloading the show, I hope you enjoy the interview!
Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CReDo Science www.credo-science.com In this episode, Dr. Ethan Russo talks to us about his new study on CBG, ‘the mother of all cannabinoids', cannabinoid acids, and affordable diagnostics for the endocannabinoid system that provide needed information for patients and doctors. This technology could improve outcomes and product choices for all phyto-therapies, such as aromatherapy, herbalism, and cannabinoid therapy, which Dr. Russo believes can be much more nimble than one-size-fits-all pharmaceuticals in addressing the individualized needs of the patient. Previously, he was Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com). He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard University, and Johns Hopkins University. He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over sixty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions. He has consulted or lectured on these topics in 44 US states and Canadian provinces and 44 countries on six continents.Useful Links:https://credo-science.com/projects/CBG StudyCReDoEndo DNA testsEurofins worldwide testinghttps://ethanrusso.org/category/library/ To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkhDisclaimer: The information presented in this podcast is for educational purposes only and is not intended to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.
Episode 27 of the Farms Not Pharms podcast finds burntmd interviewing cannabis activist, attorney, and entrepreneur Don E. Wirtshafter. Don is one of the original founders of GW Pharmaceuticals, founded the Ohio Hempery in 1990, and currently curates The Cannabis Museum, which you can check out at CannabisMuseum.com.
Biopharma deal-making activity, a closely-watched marker of industry health, remained alive and well in Q2. But whither M&A? And what's with all those $1 billion-plus deals? Join News Editor Michael Fitzhugh and BioWorld Senior Analyst Karen Carey as they chat about the latest currents in combinations, partnerships amid the pandemic, and the rising values of up-front payments – at least for those clinical-stage companies lucky enough to make lucrative deals ahead of commercialization. BioWorld subscribers looking for an even deeper dive on the numbers can read Karen's Q2 Deals and M&A overview, including overviews M&A value and volume by year, a list of the year's top M&A deals to date – led by Jazz Pharmaceuticals plc's takeout of GW Pharmaceuticals plc – and even more details about the world of biopharma deals in BioWorld Snapshots. See acast.com/privacy for privacy and opt-out information.
What is Cannabinoid Hyperemesis Syndrome (CHS)?This week, we welcome back Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis. In this episode, Dr Russo shares the latest research and findings of the largest study on CHS to date - in which his team identified 6 potential genetic targets to assist in the diagnosis and treatment of the condition.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e120About Dr. Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Paper: https://pubmed.ncbi.nlm.nih.gov/34227878/
Bright Minds Biosciences Inc (CNSX:DRUG, OTCMKTS:BMBIF) is a biotech company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Our viewers may be familiar with GW Pharmaceuticals PLC (formerly NASDAQ:GWPH), recently acquired by Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), and its Epidiolex® (CBD) oral solution as a treatment for childhood-onset epilepsy. Bright Mind’s focus is on […]
For this week’s episode, we had the absolute honour of speaking with cannabis legend, Dr. Ethan Russo, Founder & CEO of CReDO Science. As, quite literally, one of the pioneering researchers in cannabis, and someone whose insights underpin much of the modern day understanding of the plant and the ECS, Ethan is truly a Rockstar guest for the pod. Over the episode we chat through, of course, what led him to the plant, his learnings from working with companies such as GW Pharmaceuticals, and the role that minor cannabinoids are playing in his current research projects at CReDO Science. www.professionallycannabispodcast.com
We all thought it would be the strains they claimed. Turned out, it was the BRAINS. With so many major players involved in the legal cannabis space, everyone is out to protect their innovations. whether it be with their drug formulations or methods of preparation, everyone wants to stake their claim to cannabis IP. We saw the first patent on cannabis formulations with GW Pharmaceuticals and Epidiolex, the first scientifically tested medicine derived from cannabis. And as the space develops, we can only anticipate more to follow. Join @elijah__avery the digital budtender, @_n_x_t_j_e_n_, and @meyyerv as they discuss Cannabis and Intellectual Property on Outsmoken, the world's most potent podcast. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/outsmoken/message Support this podcast: https://anchor.fm/outsmoken/support
Founder and CEO of Credo Science Dr. Ethan Russo (also former Senior Medical Advisor at GW) shares his insights about the acquisition of GW Pharmaceuticals and discusses his experiences in cannabis drug development. Dr. Deb Kimless also joins the discussion to explore issues around psychedelics patents and the preservation of psychedelics producing fauna which ties into a book Dr. Russo authored 20 years ago about saving the rainforest (link below). Our scientific articles explore innovative cannabis research models and the safety of psychedelics in immunotherapy. At the end of the episode we put on our Good Manufacturing Practice hats, to play one of our favorite games. Episode's GroupJahan Marcu, PhDEthan Russo, MDNigam B. Arora, PhDDeb Kimless, MDDavid Vaillencourt, MScSarah Jane Ward, PhD (in spirit) News Links: COMPASS: We finally figured out how to make money off of hippie bean bags (3:14) https://www.vice.com/en/article/93wmxv/can-a-company-patent-the-basic-components-of-psychedelic-therapyJAZZ purchases GW for $7 Billion (11:40)https://ir.gwpharm.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-gw-pharmaceuticals-plc-creatingBeing Licked Out of Existence: Psychedelic Fauna Being Pushed to their Limits (29:20)https://www.forbes.com/sites/davidcarpenter/2021/02/02/psychedelic-toads-pushed-to-the-limit-conservationists-urge-synthetic-5-meo-dmt-option/?sh=17eeed8d9615Rapid Fire Science Study Links:Cannabis and Health Research: Rapid Progress Requires Innovative Research Design (42:17)https://pubmed.ncbi.nlm.nih.gov/31708066/ Is It Safe to Use Psychedelics During Cancer Immunotherapy? (58:49) https://www.biorxiv.org/content/10.1101/2021.02.01.429102v1 Bonus: Ethan Russo's Novel about Saving the Rainforesthttps://www.amazon.com/Last-Sorcerer-Echoes-Rainforest/dp/0789012707Today's Game (1:04:29):“Where's Vaillencourt?” a fun combination of Clue, Where's Waldo, and 20 Questions. Where we guess the location, type of facility, and type of product HLI cast member David Vaillencourt has done his most recent GMP assessment. (01:09:32) Credits:Podcast production by Joe Leonardo, Cover art by Ivan Artucovich, Intro music by Buddha by Kontekst, Transition and Outro Music by K. LOUK. Special thanks to Julian Amkraut for supporting this episode. More at: howtolaunchanindustry.com marcu-arora.com
Ireland-based biopharmaceutical company Jazz Pharmaceuticals buys the biggest acquisition in the cannabis industry to date after agreeing to buy GW Pharmaceuticals for $7.2 billion last week. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
Jazz Pharmaceuticals has been successful at building and commercializing a growing pipeline of therapies to treat rare neurologic conditions and hematologic cancers. Central to its strategy has been the use of acquisitions to build its pipeline. In fact, we should note that since recording this podcast, the company continued that approach with news that it would acquire GW Pharmaceuticals for $7.2 billion to expand its neuroscience portfolio. We spoke to Robert Iannone, executive vice president of research and development and chief medical officer of Jazz about the company's neuroscience pipeline, its growing family of commercial products, and how its preparing to maintain its leadership in the treatment of the rare sleep disorder narcolepsy as new competitors move toward market.
FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the week's most important news in pharma and biotech including Pfizer's revenue expectations for its COVID-19 vaccine, the announcement that Ken Frazier will step down as CEO at Merck & Co. and why approval of aducanumab is so critical for Biogen.
GW Pharmaceuticals, creators of the first patented cannabinoid drug Epidiolex, is to be acquired by global pharmaceutical firm Jazz Pharmaceutical. Valuing the acquisition at a little over $7 billion US dollars, the move has been seen as a big splash by many in the
After you smash the notification bell, since our information is time sensitive, you'll want to share this episode to all of your socials including IG story. In this episode you'll learn what to when your stock goes to the moon! Because profits aren't yours until you ring the register. Vettz and G-Money have a little bit of a brag session on the news that Jazz Pharma (yes that's a real company) decided to buyout GW Pharmaceuticals sending GWPH stock soaring 50% and bagging G-Money the coolest $9K ever. This was discussed in depth on what GW does in episode 11 as a pharmaceutical grade cannabis company developing drugs for diseases in multiple sclerosis among others. Listen in to find out what G-Money is gonna do next! Buy, Sell, Hold? A mix of all three? Listen in! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
“Oneness...Forgiveness...Happiness...Feeling fuzzy.” We have a narrow range of words to describe complex feelings. But this group of underground scientists are using psychedelics and cannabinoids to trace the pathways in the brain that create those intricate feelings. This podcast is the cutting edge of psychedelic neuroscience, and it is mind boggling! One of the great things about traveling in cannabis and psychedelic circles is that you meet all sorts of geniuses working away in their own corners trying to understand things like the biochemical basis of consciousness and other tiny, insubstantial matters. These men and women look like normal, everyday people but when they open their mouths you realize that their brains function quite literally, at a higher level than yours. This happens to small-brained people like me frequently.Cody Gibbons is one such big-brained psychedelic neuroscientist who I met in the Bay Area over the summer. He has worked on cannabinoid research at companies including GW Pharmaceuticals, and is currently researching "psychedelics as tools to clarify the mind/body interface.”I had to know more. For example, he told me, “You can make high doses of melatonin psychoactive with THC. This produces the feeling you get at nightfall or dusk, when the sun goes down and the body begins to relax. A shift occurs, sort of the way your iPhone goes dark at night. Typically, we don't feel that shift unless the sun going down, but you can actually induce it at dawn with this THC/melatonin combination. You get the clear feeling that the day is ending in the morning.” That’s pretty provocative. To some extent it explains why psychedelics open what Aldous Huxley called “the reducing valve of consciousness” and make us feel so expansive when we use them.Rather than attempting to concentrate the many subjects this podcast covers into a few paragraphs, let me instead give you a few nuggets to chew on. I hope they will lead you to press the “Play” button and thereby expanding your own consciousness. “A lot of people understand “I feel fuzzy.” “Fuzzy” was a term coined by someone on psychedelics who felt soft on the inside. That’s an easy one. Our work is to understand the neural pathways of the more complex emotional states that most of us have.”“There are two types of forgiveness and two corresponding receptor groups. There’s forgiveness of self vs. forgiveness of others. As anyone who has ever taken MDMA knows, you can induce forgiveness of others without feeling forgiveness of self.” “Analogs to LSD are not technically scheduled. You can buy them and even potentially distribute them legally. Put them in a baggie that says 'not for human consumption' and give them away.”“I’ve realized that consciousness is something completely different than what anyone thought. There’s been a lot of focus on the anatomical structure of the brain. Of course that’s important, as it contributes to the function of our bodies. But the function of mind doesn’t stem from the anatomical structure, but more so from the receptor population patterns in the brain. We have all of these neurons, that each express different sets of receptors. These receptor populations stretch across different neurons and not others. Our consciousness is really a function of this super advanced biochemical computer — that’s not a surprise. The surprise is that it’s more biochemically based than electrically based.”If you’d like to learn more, check out these links.Thomas RayProfessor/work breakdownShulgin publishing on Tom Ray's workYoutube video presentationsAlexander ShulginRick Strassman: DMT The Spirit Molecule
On our first podcast of the 2021, Lancaster Farming talks to Hunter Buffington, the executive director at the Hemp Feed Coalition, a group that advocates for federal approval for hemp and its byproducts for use as animal feed. The coalition’s vision is to give hemp producers and processors access to the billion dollar animal feed and supplements market. The pathway to federal approval is time consuming and complicated, requiring research and testing for all components of the plant and for each species. The task at hand is daunting, but Buffington believes it will ultimately be successful – a win-win for hemp farmers and livestock producers. Hemp Feed Coalition https://hempfeedcoalition.org/ News Nuggets What's Happening in the 'Canopy Growth v. GW Pharmaceuticals' Lawsuit? https://www.hempgrower.com/article/canopy-growth-gw-pharmaceuticals-lawsuit-extraction/ Improved THC Testing Could Be Ready by the End of 2021 https://www.hempgrower.com/article/hemp-thc-testing/ Humboldt County Planning Commission considers permanent ban on industrial hemp https://www.times-standard.com/2021/01/05/planning-commission-considers-permanent-ban-on-industrial-hemp/ Dr. Rand Paul Introduces HEMP Act to Relieve Unnecessary Constraints on Hemp Industry, Provide Transparency and Certainty https://www.paul.senate.gov/news/dr-rand-paul-introduces-hemp-act-relieve-unnecessary-constraints-hemp-industry-provide Pennsylvania Sees Great Promise for Hemp in 2021 https://www.hempgrower.com/article/hemp-pennsylvania-sustainability/ Alabama hemp company launches new fiber processing plant https://hempindustrydaily.com/alabama-hemp-company-launches-new-fiber-processing-plant/ These Hemp Flower Cigarettes Can Help You Kick Your Nicotine Habit https://futurism.com/oklahoma-smokes-hemp-flower-cigarettes USDA Approves Hemp Production Plans for Rhode Island, the Soboba Band of Luiseno Indians https://www.ams.usda.gov/content/usda-approves-hemp-production-plans-rhode-island-soboba-band-luiseno-indians Pennsylvania Hemp Summit https://pahempsummit.com/ Check out the Southern Oregon Hemp Co-Operators' 2021 Golden Grow AwardsJanuary 30, from 11 AM to 6 PM at the Ashland Hills Hotel in Ashland, OR. The event will be held in accordance with CDC Covid-19 safety guidelines and will be livestreamed via megatron technology. https://soorhempco-op.com/
Canadian cannabis producer Canopy Growth is suing Britain’s GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma’s revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers.
Canadian cannabis producer Canopy Growth is suing Britain’s GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma’s revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers. --- Support this podcast: https://anchor.fm/talkinghedge/support
Canadian cannabis producer Canopy Growth is suing Britain's GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy's intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma's revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers.
Cannabis News Update December 22, 2020 Today in the world of cannabis: Body and Mind receives a cannabis distribution license in the state of Nevada, GW Pharmaceuticals publishes Phase 3 clinical trial results of EPIDIOLEX, and a coalition of organizations urge the New Jersey governor to issue pardons for those convicted of cannabis-related crimes. The Morning Buzz presented by TRICHOMES brings you late-breaking news that tells you what's happening within the cannabis industry. Check in with the cannabis community at TRICHOMES.com
Can metrics play a crucial oversight role in establishing an effective and efficient relationship between sponsors and CROs? That’s one of the important issues discussed in Steve Crow’s and Keith Dorricott’s interview with Linda Sullivan, MBA, Executive Director of WCG’s Metric Champion Consortium (MCC). Crow, Associate Director, Performance and Training, Clinical Operations at GW Pharmaceuticals (known as Greenwich Biosciences in the U.S.) explains that the growth of the company’s portfolio of studies led them to seek CRO services - which began their journey of establishing a core set of CRO metrics to assist with oversight. The organization joined MCC to learn about metrics and gain access to the metrics toolkits available to members. His advice to other sponsors in similar situations, “Don’t reinvent the wheel … MCC has the resources you need to get started”. He notes that it’s important to find a “common purpose” by focusing on the key questions you seek to answer rather than giving CROs a list of performance metrics. Opening the discussion with key performance questions that are important to your organization results in enthusiastic discussion, collaboration, and the removal of barriers, explains Crow. Keith Dorricott, a Lean Sigma Master Black Belt with extensive experience in process improvement at CROs, is now Director at Dorricott Metrics & Process Improvement Ltd in the UK, notes that metrics are only beneficial if they answer specific performance questions. Indeed, Sullivan says, that’s the basic approach MCC advocates by including key performance questions in the metric toolkits and implementation support tools available to MCC members. Finally, Dorricott and Sullivan point out, context is vital not only when selecting metrics but also paramount when reviewing results. Collaborators should remind themselves of why they’re looking at the data, what the key questions were, and what actions should be considered if performance does not meet expectations. The metrics should drive decisions and action. Otherwise, they note, they’re just looking at numbers on a dashboard.
O uso medicinal da maconha divide opiniões no Brasil e no mundo. Mesmo com a eficácia comprovada para algumas doenças, uma parcela significativa das possíveis utilizações ainda não possui efetivação científica por meio de pesquisas ou está em fase de estudos. Além disso, existe uma preocupação com a padronização da fórmula dos compostos. Dentre os mais de 100 fitocanabinóides, apenas dois são estudados para utilização em remédios – o tetrahidrocanabinol (THC) e o canabidiol (CBD), que estão presentes em maior abundância na planta e são o princípio ativo de medicamentos feitos a partir da Cannabis. Em todo o mundo, o primeiro fármaco aprovado foi o Sativex, um spray bucal utilizado no tratamento de esclerose múltipla e fabricado pela empresa farmacêutica britânica GW Pharmaceuticals desde 2005. Já no Brasil, o remédio é comercializado com o nome de Mevatyl pela Ipsen Farmacêutica, sendo a única medicação derivada de maconha aprovada no país – foi registrado pela Agência Nacional de Vigilância Sanitária (Anvisa) em 2018. Quer saber mais sobre o assunto? Então, ouça agora o novo episódio do Papo Secad! Entrevistamos Rafael Guimarães do Santos, professor de Neurociência e Ciência do Comportamento da Faculdadade de Medicina da USP de Ribeirão Preto, para explicar como são extraídas as substâncias, quais os principais medicamentos, seus usos terapêuticos e as evidências sobre o uso para fins medicinais.
Vettz and G$ are back jumping into the ever so wild medicinal cannabis field. The company they will break down is GW Pharmaceuticals (NYSE: GWPH). They have two products Epidiolex and Sativex both phytocannabinoids synthetically derives from the cannabis plant. You're going to get the full breakdown on financials, how much the stock is, where their products are approved, and mostly importantly if we think this is a great play going forward! Listen up and share this post with your friends on social media @allininvestingpodcast. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
The Dow started the week, closing up 328 points and Jim Cramer's breaking down today's headlines and getting investors ready for the trading week ahead. Then, as the long-awaited IPO Snowflake comes public this week, Cramer is taking a closer look at the company and making sense of what to do with the stock. Then, GW Pharmaceuticals CEO Justin Gover checks in to break down the company's most recent quarter. Plus, how could vaccine hopes be impacting the market each day? Cramer's breaking down all the stocks that are moving the most on headlines for a COVID treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices
How has cannabis and the endocannabinoid system evolved over time? This week we welcome back the legendary Dr. Ethan Russo, one of the world's leading authorities on medical cannabis and botanical therapeutics, both as a physician and researcher. This episode, we discuss the origins and evolution of both the cannabis plant and the endocannabinoid system. We also look into how the biochemical diversity of cannabis has been altered by humans over time.View full show notes and summary here: https://www.cannabis-conversation.com/blogs/episode67About Dr. Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex.He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He joined GW as a full-time consultant in 2003.He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences.He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, and phytocannabinoid-serotonergic and –vanilloid interactions.
What are terpenes and how important are they to the cannabis plant? This week we're joined by Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis. In this episode, we discuss all things terpenoid, including how they are produced, varieties commonly found in cannabis, and their therapeutic benefits. Episode SummaryDr. Russo was classically trained as a neurologist, but turned back to a teenage interest in medicinal plants when he realised he was prescribing increasingly toxic drugs to his patients. In the early 90's he became interested in treating headaches and migraines, and took research trips to the Amazon rainforest in Peru to work with native tribes who treated the condition with botanicals.When he returned to the USA he knew that he wanted to change his career path, and became interested in the medicinal properties of essential oils, terpenes and terpenoids.Dr. Russo became interested in using cannabis medicinally and started the Journal of Cannabis Therapeutics. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals who had obtained a permit to grow cannabis for medicinal purposes in 1998.Later on he became a Senior Medical Advisor and was heavily involved with the development of Sativex and Epidiolex.The first cannabis derived pharmaceutical approved by the FDA was Epidiolex, which contains a 98% pure cannabidiol compound and is used to treat Lennox-Gastaut syndrome and Dravet syndrome.To get a drug approved by the FDA often requires between 10 and 12 years of research and between $700m and $1.2bn of expenditure.Dr. Russo has recently founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system, outside the realm of THC. Projects include over the counter treatments, novel extraction techniques, nutritional cannabis products, cannabis based disinfectant, and diagnostic tests. Terpenes are the aromatic components of plants which can be found in the leaves, bark, flowers and sometimes roots. They are used in aromatherapy which is the science of essential oils. An example of this is lemon oil, which denotes cleanliness and is a cleaning agent. The terpene responsible for this aroma is Limonene, which can be found in citrus fruits.Selective breeding for high THC strains means that many of the new strains have a dominant terpene of Myrcene, which interacts with THC to produce sedative effects.Dr. Russo is currently conducting a piece of research which looks into the effects of using THC with differing terpenoids, using memory tests as a measure.There are over 20,000 identified terpenoids, none of which (so far) are unique to cannabis. Alpha Pinene and Limonene are the most abundant in nature but are not found in cannabis very often. In cannabis, Myrcene and Caryophyllene are often found, which interact with CB2 receptors. Caryophyllene is both a terpene and a cannabinoid.In any cannabis sample, there are on average 3-5 prominent terpenoids along with trace amounts of many more.Terpenes act as a defence mechanism for plants, their strong smells either promote pollination, deter predation by insects or to prevent grazing by mammals. Cannabinoids and Terpenoids are both produced in Capitate Glandular Trichomes which are most abundant in unfertilised female plants. Many terpenes have pain reducing effects which work through distinct mechanisms. Quotables‘Terpenes are critical components to the medicinal effects of cannabis' 04:20‘Essential oils are extremely potent, so the amounts involved are tiny' 22:25
We are excited to announce CannMed 2020's Keynote Presenter in the Science Focus Area is Dr. Ethan Russo. The title of Dr. Russo's presentation is “Cannabis and Psychiatry: The Final Frontier”, and it will explore basic science and clinical trial data to assess the role of cannabis psychopharmacology with respect to issues of impairment, depression, insomnia, PTSD, schizophrenia, anxiety and addiction. You can hear about this fascinating topic and more in our latest episode of the CannMed Coffee Talk Podcast, where Dr. Russo joins us as a guest. This is a great episode for listeners who are new to cannabis medicine because Dr. Russo covers some of the basics, like "what is the endocannabinoid system?" Having said that, there is still plenty of meat on the bone for more advanced listeners. Use the player at the bottom at the post to listen. Dr. Russo began his career as a physician, board-certified in Neurology with a Special Qualification in Child Neurology, but he has always held a strong interest in medicinal plants, which he gradually incorporated into his practice and research endeavors, with the intention of bringing cannabis-based and other botanical agents back into the mainstream of medicine. He is a graduate of the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington, and was a clinical neurologist in Missoula, Montana for 20 years. After his clinical experience, he began dedicating his career to developing innovative approaches targeting the human endocannabinoid system to produce dramatic results for patients suffering from a range of neuro- and immuno-based diseases and disorders. From 2003 to 2014, Dr. Russo was instrumental in developing both Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. In 2015, he became Medical Director of PHYTECS, a company devoted to the research and development of medicines, supplements and lifestyle approaches to optimizing the function of the endocannabinoid system (ECS), the critical homeostatic regulatory mechanism of human physiology. From 2015-2017, he was Director of Research and Development for the International Cannabis and Cannabinoids Institute. Dr. Russo has also held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, the Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council and has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany, and he has consulted or lectured on these topics in more than 30 US states and 30 countries. His current venture, called CReDO Science, aims to advance cannabis-based and botanical therapeutics via the development of optimized chemovars and extracts, as well as pursuing novel formulations and diagnostics related to the endocannabinoid system. More information can be found by visiting https://credo-science.com. Needless to say, we are delighted to have him as such an important part of CannMed 2020. SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS! Related Links: Ethan Russo, MD CannMed 2018 PresentationEthan Russo, MD ResearchGate ProfileCReDO Science LLC Website
Medical use The 1998 regulations under the Misuse of Drugs Act 1977 (as amended) listed cannabis, cannabis resin, cannabinol and its derivatives as schedule 1 drugs.[14] For such drugs, manufacture, production, preparation, sale, supply, distribution and possession is unlawful for any purpose, except under licence from the Minister for Health.[15] Licences were granted to GW Pharmaceuticals in 2002 and 2003 to allow medical trials of the cannabis extract nabiximols (Sativex) in a county Cork hospice and Waterford Regional Hospital.[16] In 2014, the 1998 regulations were amended to allow nabiximols to be prescribed by excepting it from schedule 1.[17][18][19] The first licence for medical use of cannabis oil was issued in December 2016 to allow Tristan Forde a two-year-old boy with Dravet syndrome to continue treatment begun in Colorado.[1][20] This was issued by the minister after an application by the boy's physician.[1]weki Reform Luke 'Ming' Flanagan, a longstanding pro-cannabis campaigner, was elected to the 31st Dáil in the 2011 general election as an independent Teachta Dála for Roscommon–South Leitrim.[21] On 6 November 2013, he proposed a motion "That Dáil Éireann calls on the Government to introduce legislation to regulate the cultivation, sale and possession of cannabis and cannabis products in Ireland", which was defeated by 111 votes to 8.[22][23] On 20 November 2013, he introduced a private member's bill, the Cannabis Regulation Bill 2013, which never got a second reading.[24][25] In November 2015, Aodhán Ó Ríordáin, the Minister of State responsible for the National Drugs Strategy, said he favoured decriminalising #cannabis, cocaine and heroin for personal use.[26] Ó Ríordáin lost his seat at the 2016 election. In December 2016, a private member's bill was introduced by Gino Kenny of People Before Profit to make cannabis available in Ireland for medicinal use.[27] It passed second stage without a vote.[2][28] The bill progressed to the amendments stage on 9 November 2017.[29] One of the major organisations campaigning for the legalisation of cannabis in Ireland is NORML Ireland. 'NORML Ireland supports the removal of all penalties for the private possession of cannabis by adults, cultivation for personal use, and the casual nonprofit transfers of small amounts. NORML Ireland also supports the development of a legally controlled market for cannabis'.[30] In June 2018, after a bill was passed to legalise cannabis in Canada, Taoiseach Leo Varadkar stated that the #decriminalisationofcannabis was 'under consideration', with an expert group considering the examining the systems in jurisdictions in which cannabis has been decriminalised for recreational use.[31 weki --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/vegansteven/message
After hitting an all time high today, Cramer’s heading out west to Redmond, Washington, where he’s sitting down with Microsoft’s CEO and CFO after the company announced its plan to be better than carbon neutral by 2030. And, last night before leaving San Francisco, Cramer spoke with GW Pharmaceuticals CEO to learn more about the company’s 4Q ‘19 pre-announcement and the success of its cannabis-based drug, Epidiolex. Learn more about your ad choices. Visit megaphone.fm/adchoices
All right. Welcome to the gut check project. I'm here with your host, Dr. Kenneth Brown. I'm Eric Rieger. This is gut check project, Episode Number 26. We're going to wind up 2019 with some awesome info. What's up, Ken?What's going on Eric? How are you doing, man? Episode 26. Unbelievable. I apologize if I'm a little too sexy today because I'm just coming off of a small cold. I think the hottest people are those that are sick.Well, I'm not sick. I'm post sick. Remember, the viral prodrome. The reason why we always like pass so many viruses is that you tend to pass the virus before you even know that you're sick by the time you're actually sick. You're probably okayYeah. At that point you can go back and say I heard you might be sick. I was too back then.Yeah, exactly. Good to see you?Well, today's episode is going to be pretty awesome. We're going to tackle number one, we've received tons of email in your clinic because you also sell the KBMD CBD at your clinic, you get these questions. These have been coming in Fast and Furious over the last little over 14 days. And it's questions about the safety of CBD oil and its application. So we're going to tackle that I do need to tell everyone. Thank you. We're on episode 26 because the first 25 shows were so well supported by all of you who've been keeping up with a gut check project. We grow every single day. Paul, the guy who's helping us put together the production now and helping us spread the word. We just hung up the phone with him. We've gotten more and more downloads each week. So thank thank you every single one of you for liking, sharing, emailing, telling your friends about it. We sincerely appreciate it.We learned so much about it like today we have a new a different guests we do Instead of gutsy our little mascot or green frog, but since we do film on a green screen, he gets blocked out did not know that didn't even realize that. So now we're going to go with a dung beetle, right here? Yeah, yeah, we did. So that's Dilbert, the dung beetle,Dilbert, the dung beetle. So one of my favorite things is whenever we're bringing any patients back and somebody sees you, and they're like, hey, you're Eric, I watch your show that just warms my heart. So if you happen to be a patient and show up and you watch the show, if you say that it just makes us both feel really, really well...needed wanted, appreciated.Yeah. At least outside of me putting you to sleep. Take five or six good deep breaths. Exactly. Today's episode is sponsored by Atrantil. Your bloating relief, it's what we do. So go to Atrantil.com or lovemytummy.com/KBMD. Today it's also sponsored by KBMD CBD oil. You can find your own KBMD CBD oil at kbmdhealth.com which of course, the initials KB, Kenneth Brown, it's endorsed by the guy who's sitting across the table from me. So Ken, why is...What does MD stand for? Well, I'm not really sure.I thought it was your buddy Mike Doyle, but I don't know.Yeah, it's probably. So tell us a little bit about KBMD CBD. Alright, so KBMD CBD oil. I got involved with the science of CBD because I saw the beneficial effect with my patients when we developed Atrantil I then learned that the science of Atrantil the polyphenols in it actually augment CBD. So I'm seeing this combination do incredible things for people. So this particular CBD is one that we have researched, I've seen it work clinically. And we know that it comes with a certificate of analysis. It is organically grown, it is naturally extracted with co2, so it meets all the criteria that you want in your CBD because this is important. The rest of this podcast is going to be all about the dangers of CBD.Definitely and It's really interesting since we do have so many people who have begun to purchase CBD find benefit. It's really kind of weird what's occurred over the last two weeks. And what I would say is a little bit of misinformation. But it's more or less probably just misunderstood information and or or misapplied information. But regardless, the benefits of CBD used correctly, have been undeniable with the people who've come back through the clinic with people that we've scoped, and how well that they are doing. And so, hopefully today, we're going to provide some context on why more or less the dangers that you may or may not have read about in the news recently are really a little concerned. But we'll, we'll see. We'll see how far along we get in at the last. The last thing. Our last sponsor is the KBMD health box. You can find KBMD health box by going to kbmdbox.com. Now last week we did a full unboxing which is something I think we're going to try to do at least once a month. But essentially, if you want almost $300 of physician vetted supplements that can help you benefit your life and get them for only $147 which you would spend, not you would spend more than $147 worth of time driving somewhere to pick them out for yourself and having someone handpick them for you. Go to KBMDbox.com. What was one of the things that we had a patient come through just earlier this week, who showed us his lab results that he took to his primary care physician? So we're starting to make a difference in the landscape of health here in the DFW Metroplex and different places. I've been getting emails and calls from people around the country that will actually hear the podcast and then they'll want to sign up for the box. And what we're seeing is that these vetted supplements actually are making a difference with both subjective how they feel and objective the labs. So the reason why I chose these things is they all have third party analysis. And they all have some scientific background that actually explains how they're going to help you. So much so that I'm thinking of ordering my household, another box. So although it is the KBMD Health box, I actually I love the fact that I can get these things that I'm going to purchase anyways, they come into my house, so my whole family's on it. Now we're running out of stuff. So I'm gonna end up having to double up on everything. So it's one of those things that I feel really good that we can look at different aspects. And when somebody says, Oh, I tried X, Y, and Z, I didn't notice anything. I'm like, oh, did you try one that had a third party analysis? No. And then they do and they're like, Oh my gosh, big difference. Same thing with CBD. I mean, a lot of CBD out there doesn't really have what's on the label. And we're going to get into that because we're going to talk about what the FDA thinks about it. We're going to talk about the different media and what they're doing, and hopefully get into all that but that's the whole point of that box is I want to deliver these vetted things to your house monthly so that you can continue to improve your health. Hundred percent. So without further adieu, be sure to like and share the gut check project. We certainly appreciate all of the support to date. We're going to hop right into it. So what we've received here recently is a lot of speculation and concern from people who have said, Hey, I'm interested in CBD. I know that you and Dr. Brown have heavily studied, been entrenched with CBD and its application over the last few years. I just learned that the FDA is associated or made public a study that says that it may be hepatic toxic or bad for my liver. It's, unfortunately, it's a weird jump off point. So I'm going to kick it to you. Because immediately I had lots of different thoughts and instead of getting emotional, what did we do? We went and tried to find the sources of where this information came from. We want to backtrack on how they got to that conclusion. And I think that we can put a lot of questions at ease and even help people learn how to be a little bit more critical with the data that they receive when they receive it. Because let's face it, lots of stuff that we see on the internet, or that we hear on the news or reading the paper, it's basically clickbait. It's basically things to keep you engaged, whether or not the actual substance is worth the headlines that are written so...So what you're referring to is recently the FDA put out a statement, a consensus statement in the news and it's making all kinds of traction in the news that they're saying that CBD is not as safe as people think not only that it can be harmful. Now this has bled onto TV and my patients have been asking me about this FDA statement. Then there's been other news articles like the one that Forbes published, read said that CBD causes liver failure. Failure. That was the title liver failure caused by CBD. I want to get into all that I wanted to take a really deep dive into the science of all of this as a gastroenterologist, I'm board certified gastroenterologist, which means not only am I a simple country, butt doctor from Texas, but we actually have to learn liver disease, hepatology, I'm not a hepatologist like some of my other friends where I send like really complex things, but we at least have to understand the liver, how it works and what it does. So a lot of these articles discuss this but they don't clarify so many little things. Because and they shouldn't it's a it's a journalist writing an article they want they want it to be shared. And anytime you mentioned CBD, anytime that that is thrown out there, you're going to get some clicks, you're going to get a whole lot more clicks. If you say you're going to die from taking CBD. It reminds me of the I remember Jerry Seinfeld was on Saturday Night Live one time and they were making fun of the nightly news where they always do the promo at like three o'clock. Like five household items that are guaranteed to kill you, tonight at six.You're like what? If it was so important, they probably wouldn't make you wait.No, I'm gonna die before you put this on the air. So what I'd like to do is talk about the briefly the science of the endocannabinoid system and CBD, then do a little bit deeper dive into the liver. So everyone's going to get a primer on the liver 101 here, because these studies don't make sense unless you know, some of this knowledge. It's just sensationalism. For some of it, some of it is a little bit unfair. I think some of it is for what the FDA got, and it's there. But I just want this podcast today to be something that can be useful for industry people that can be useful for patients or people that are thinking about taking CBD and it can be useful for a subset a small subset of people that may be should not consider taking it. Yeah. So all of this is kind of, you know, for the future of this podcast, It's almost going to be a bit of a rebuttal. Not necessarily a defense of hemp derived CBD. But let's just buckle up and kick some science. This might be a little bit I don't know how long we're going to go where we're going to go with this. We're just going to feel it out and see what happens. But I at least want to be able to explain why I still believe that a lot of people should be taking CBD even though Forbes is like you're gonna die from this.Yeah. It's not arsenic people. No it isn't and I think another cool application here is there are people out there who have been on the fence on whether or not I should try CBD or is this something that's good for a family member for me? And unfortunately, there you hit this intersection, where a news headline is written that CBD causes liver failure. Well, if they've been on the fence, that's a pretty big No, no, right? So now you've taken away maybe an avenue that they were considering to help them out. What I hope that we can do with this particular episode is basically let's temper and let's see things in context. I think context is a word that as you get into sensationalism is something that is kind of the rescue item. If I could put something into context, then at least I'm giving someone a fair chance to understand the information that's before them. I don't feel like sensationalized headlines do things like that. Then again, I also don't feel like someone who shakes, hand picked or cherry pick studies is doing that either. So what I think today that we can do is fairly evaluate and talk about the process of how the liver works, and why some of these studies are or are not applicable to the nature they were presented.Absolutely. So the first one we got to discuss is what what what the heck did the FDA say? Sure. So the FDA came out and they mentioned that they've got several issues with the safety of CBD. The two main ones that they're really concerned about are potential for liver injury, and interactions with other drugs. What they actually said is that they're concerned that people may mistakenly believe that trying CBD can't hurt the agency wants to be clear that they have seen only limited data about CBD safety. And these data point to two real risks that need to be considered as part of the drug review and approval process for the prescription drug containing CBD. Interesting. Now, what I say this is because the FDA is referring to the data that was presented to them by GW Pharmaceuticals, who has a epid... eipdi..x you know?E-p-i-d-i-o-l-e-xYes, which is the first FDA approved prescription CBD isolate,Right,for seizure disorders.It's important to point out that is not full spectrum. Correct. That is not full spectrum. And there's some that's important because here later in the podcast, and think we're going to draw some comparisons and just if you're listening, just remember, epidiolex is a CBD Only isolate it is not a full spectrum product.So let's talk about what the FBA what the FDA actually does. So the FDA has a really daunting task. The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy and security of products. So it is super daunting because there's a lot of products hitting the market, and the FDA has tried keep up with this to try and protect people. And let's be honest, let's look at the elephant in the room. The elephant in the room is that there are a lot of bad CBD products out there. Yep. In fact, in a jam article 2017 showed that 70% of the CBD products that they looked at did not have what was on the label and what was there could be higher levels of CBD could be lower levels of CBD. So it's a gamesmanship that's going on right now. So it is totally true that you need to make sure that you've done your homework on what type of CBD that you're actually taking. There currently is little to no regulation in the CBD industry. There is the President and CEO of Natural Products Association NPA. His name is Daniel Fabricant. He's a PhD. I love this quote. He's quoted as saying it is well past time to bring science into the equation, as federal rules require safety and Consumer Protection must come first. I agree. And we all agree with that. Sure. And I think that all companies that have reputable CBD companies, they all want that. Problem is when you have these different stories leaking out, which gain much more traction, it just starts creating a little bit of confusion misconception, and then people don't really know where to turn. So the feeling is, is that possibly statements by the FDA saying that it creates this narrative that questions the safety of CBD overall, strictly to address a few number of companies which are producing quite frankly, some crap products.What was the number that we learned the last time that we were in Utah at meeting I believe it was one out of every 23 to 24, I could be off it was definitely in the 20s. But every to every 23 or 24,25, CBD labels available for retail purchase. One is seen as a reputable well marketed or correctly labeled product, which means that even if it happens to be off a little bit, you've got 23 or 24 other labels which are just not truthful or probably not correct, don't have a certificate of analysis or are blatantly, just not even what's in the bottle.100%. There's a lot of people out there trying to take advantage of this wave that's coming. So I do not. I believe that the FDA is doing their job by looking at the data that was actually presented to them Agree. So let's take some time and break all this down for the consumers, health care providers, industry personnel. Starting with the question, does CBD cause liver damage? Unfortunately, or fortunately, because I like science we really need to talk about what the endocannabinoid system is. Because if somebody's listening to this, they're like, Well, I was thinking about taking this but I'm worried becasue it can cause liver failure. I don't know why I'm taking it. Why in the world should I be taking it? So let's do a quick one minute discussion of the endocannabinoid system. Let's do it!All right, the endocannabinoid system. The endocannabinoid system is a system which was discovered in the 90s that we now realize it's probably everywhere in the body. There's primarily two different types of receptors, but essentially, the way that I try to explain it to my patients, it's concentrated more so in the neural areas, nerves, brain and the immune areas. Although we now know it's in every single organ, that's where all the original research was. We now realize that its job, the endocannabinoid system is to produce these products called endocannabinoids. Which work as traffic cops. They just kind of get your body to get back to an area of balance. If you've got too much activity, they go Whoa, slow down a little bit. If it's not enough, they go, come on. Let's go ahead and get some more going here. So you have this fantastic system in your body that really just tries to keep balanced. Think of it that way. And you're going to hear a little bit later why I think most of America is out of balance. I think most of America needs some replenishment of their own endocannabinoid system. So that's the important thing is is that there's a dire need to try and get us all back to a certain balance, because the reality is we're getting sicker as a nation. And one of the causes could be that we took hemp derived foods out of our diet and out of our livestock diet. And there's a theory on that, that possibly that's one of the reasons why we're having more autoimmune diseases, why we're having more of the other problems that we're seeing, Well at least contributing factor.Certainly at least a contributing factor. So keep this in mind. So the the primer on the endocannabinoid system is if you're, if you have ears and you're hearing this, you also have an endocannabinoid system, and you have a higher than likely chance that you are out of balance with that. And if you are out of balance with that, then you probably could benefit from some of this. Sure. So right now you're going well, I'm out of balance, I'm going to probably benefit but I'm going to go into liver failure if I do this. So let's talk about what liver failure means. You have a genius living within you. You probably have multiple geniuses living within you.Thank you. That feels great. Sometimes the voices in your head don't say to do bad things.The evil genius. Yeah.Well, one of the geniuses living within you as this beautiful origin called your liver. So you have this and it's amazing. So to understand where they're going with this, let's talk about what the liver actually does. So we all have livers. And they work differently in every single person, and they can continue to adapt, evolve and change. One of the only organs that you can transplant a partial portion of it and it will grow into a full liver. So the nephrologist think that the kidneys, the smartest organ, the neurologists will think that the brain is the smartest organ The cardiologist says if you don't have blood, you can't think so It must be the heart. Yeah, yeah, exactly. I'm gonna say, well, for health span, smartest organ in the body is the endocannabinoid system. So eventually, we're going to have Endocannabinoidologists. Because what ends up turning out is that the endocannabinoid system is in all these different organs.Correct.They're not completely separated. So let's talk about the liver. The liver is responsible if you ever wonder what the liver does. So do you have any idea what the liver does? I've got a little bit of an idea... Little bit of an idea. So the liver is responsible for selective uptake, concentration, metabolism, and excretion of the majority of drugs and toxins, also known as xenobiotics. So let me just say that again. Basically, the liver takes the crap that you bring into the world. And it says, I'm going to convert it to something useful, or I'm gonna get rid of it for you. Yeah, it can detoxify it, or it can say, Oh, you need to be this and then you're useful. That's why I say it's a genius in your body. And it the liver figures this out, it figures out what you need, and it determines if it's a drug, or if it's a toxin, and it can turn into a better form. Now, one of the problems I have with these different articles that I've been reading, is that they discuss that then enzymatic process called the P 450 system, and they just write it like that they're like, CBD has been shown to affect the P 450 system. What doesn't affect the P450? So that's the issue. So let me break that down, I bring up the P 450 because in the lay literature without even describing what it is, it is a complex. It's called a phase one metabolism of the liver. Under p 450. It's an umbrella term that has over 60 different genes, that code for hundreds of enzymes to break down anything that comes your way. So the P 450 enzyme is like saying, Oh, I don't even know an analogy, but it's top of the funnel down. It's like you just so generic, that you can't just say that. So but they write it in the lay literature almost as a sounds sciency so I'm sure that it's, I'm sure that it's right. That's kind of my feeling on I'm like, why would and all these people it's almost like these news articles parrot each other. And nobody's stopping going, wait a minute, because as it turns out, the P450 system, not the P450 enzyme, the system breaks down almost everything that we put in our bodies. Yeah, no joke. So a lot of going back to the pharmaceutical days, I remember that was one of the biggest challenges with with any of the drugs that we detailed a physician on was, how is it affecting the P 450. And that would be something that they would be all salespeople be coached on that before they would go on calling a physician. But the truth is, it doesn't have to be a compound. It doesn't have to be a medical pharmaceutical compound for that to be somewhat important. Something as simple as grapefruit juice. Also, detectibily inhibits the metabolic ability of the P 450. So there's all there's a handful of different drugs that people who are elderly, maybe caution, don't drink grapefruit juice, because it will inhibit your ability for your body to clear this particular drug. And I say that to say this. It's not nothing is inherently just special because it does or does not directly affect the P450, almost everything you take into your body is either cleared quickly or slowly by that same system.Yeah, so they kind of imply like CBD is the only thing that gets...Not even close....that gets processed in the in the P450 system. In fact, we know that there are multiple medications that can be altered by certain foods. Grapefruit is the most common one, and that really affects like immunosuppressants tremendously and that's where it really came up. When they realized, oh my gosh, you have these different drugs, let's say blood thinners and immunosuppressants, which have a very narrow therapeutic window, you have to have these things like right dialed in. Yeah. And then people talk about grapefruit but you know, other things that have actually been shown to do this cranberry juice, black tea, pepper, even chocolate Yep. has been shown to affect drug absorption and they have been shown to affect certain pharmaceuticals. We don't even know the tip of the iceberg on this because you have to do the study on it. You have to do the pharmaco kinetics, the PK is what it's called to actually determine that which is so funny because they say oh CBD is metabolized by the P450 system. That means nothing. And so if you take CBD and or chocolate and or drink tea, be careful. I mean...I think a good analogy a seriously a good analogy is it the P450 being metabolized by the P450. It may be good for base knowledge, but the truth is, is does it overwhelm that, as you put it system, if it is overwhelming that system, chocolate, for instance, for most intents and purposes would be like a single car driving down a six lane highway by itself. It's not really if the highway was a P450 and the car was the chocolate. It doesn't take anything to funnel that that car through.Correct.The problem is is whenever you happen to overwhelm that system. And that is important to know. But I would say in terms of context, kind of the way that we started this discussion in context. It's not my belief through what I've read and seen that CBD inherently overwhelms or becomes more than a single car down that six lane highway.So not only is it just one single car going down the highway, remember that not only foods but drugs, nobody's talking about drug drug interaction.Right.So there's a reason. So I see a lot of patients that one drug may be very effective one thing may be very effective, but there's so many variables like for instance, drugs, the sex of the person plays a role, you may have different levels, the age of the person and any diseases can all affect this whole system called the P 450 which produces enzymes. So not only that, but then genetics play a huge factor, alcohol intake.Alcohol intake, all of that. I mean, genetically, this may be why some drugs work on certain people and why they don't work and others fact there's a whole field of science right now where people are trying to determine the genetics ato go, Oh, you're going to need a higher level of whatever Plavix which is one that they've actually looked at. Or you can, you're going to take less. So we this is a whole field of this beautiful science where we can go Okay, genetically, you're going to be predisposed to need more medications. So when these enzymes get used up, basically if you've got this one chocolate, which is a car, one on six lane highway, and then you add fluconazole, which is an antifungal, that's an but that's not a car, that's a semi now and then you add alcohol, which is a minivan could be ccould be a couple minivansand then you do whatever something else, but you can see that the liver has to try and process this right. So what happens is it becomes this once it becomes a traffic jam. Then people start getting angry, they start honking their horn that is a rise in your what we call lfts liver function panels liver function test Yeah, so AST and ATL are the two ones that we always talk about, that's exactly what the FDA was referencing. So I want everybody hear this. When you overwhelm the liver with multiple cars using your analogy, then honking starts and the honking the warning sign is this rise in AST and ALT. So, for instance, your body can adapt to it. We've seen this all the time. If you drink alcohol on a regular basis. you build more lanes, you build more lanes, you get really good at metabolizing alcohol. Build tollways. I'll use myself as an example.Not with alcohol.With coffee, Okay.I always have to laugh. Whenever I go to the my own doctor. They say how much coffee do you take? I just write obscene amount because I've down regulated by receptors or I've had the ability to ramp up my my livers ability to convert that coffee into an inert thing and there it is. So you see it as an anesthesiologist or as a crna. I mean, describe what your experiences whenever you try and put somebody to sleep using propofols, different medications.Yeah, well, I mean, definitely, if someone says that they happen to be a large consumer of or a consumer of large amounts of alcohol, it generally takes anywhere between 20 and 30% more of an agent to put them to, to sleep safely, say, But back to your point of body habitus, for whatever reason, even just something as simple as someone being a redhead fair skinned, those people generally take more agent to make them go to sleep. Yeah, let's go ahead and clarify this. This is a well known thing in anesthesia. You're not being prejudiced? No, not at all. No, they literally just for whatever reason, the metabolism rate of someone who's fair skinned with red hair is typically higher than the average calculation and you can go through any types of weight based medications that we use to bring sedation to someone and generally fair skin redhead folks just take more. Is that interesting?Yeah, it is. So that is more than just anecdotal like they've actually done some studies on this and they've actually shown probably because whatever lineage, they come from Scotland, Ireland, they have a higher P450 to metabolize that particular or a higher subset of the P450 systems. So just keep that in mind. So when you take certain foods or drugs, everything's competing for your liver, to do to just say, hey, fix me, you know, figure out what's going on. Fortunately, it is a badass organ and the liver is tough and it can handle a lot, the largest solid organ that we have in the body. So usually it can handle everything. Now the most common example like we've talked about, if you take grapefruit juice with certain immunosuppressants and things then that particular combo because those drugs need exact or how they were manufactured need exact metabolism numbers. Not only that, did you know that like nutrition plays a big role. So, high protein diet will actually affect your P 450 and malnutrition will affect it. of course it will. So those are all of our paleo friends over at paleo FX and such those guys have revved up p 450s. Eating a lot of protein working out a whole lot, they're able to do this. Unfortunately, malnourished people probably can't tolerate as muchNo and they aren't they aren't they honestly they don't have the supply to rebuild the enzymes that are that are used within the P 450 I mean it's just malnutrition is going to deplete all different types of systems, not just the liver.So in the intro, I kind of mentioned that we're getting sicker. And so let's use nutrition as an example. federal policies tightened by the controlled substance act of 1970 essentially banned the production of industrial hemp during the war on drugs effectively we made hemp CBD illegal and put it under the umbrella of cannabis cultivation. Now what were we were talking with Will Clyden of O-hi energetics right, who actually discussed this and he said some cool stuff on this. He back before this when they were they were using hemp and hemp has been used for ever like since we landed in America, hemp has been using hemp has been used in China for thousands of years and all this other stuff that we were feeding because it's a fantastic crop. It's it detoxifies the soil. And it actually works. It grows quick. It's a great crop industrial. What were we thinking making it a banned substance, I don't know, separate discussion. But they've got data to show that when they were feeding chickens, so for everybody out there I had a patient today who said I said Oh, she was suffering from some things and I think CBD would help with and I mentioned Hey, have you ever considered CBD Oh, I would never ever, ever, ever do anything like that. I am not like that. I said, Okay, that's cool. said hey, let me tell you something. Do you know that before 1970 we were actually feeding animals like chickens and cattle. One of the primary things that we would feed them would be hemp, and it's been shown that you can take a chicken egg and it had over 250 milligrams of CBD, right so right now if you're somebody that just spent $200 on your CBD that has 300 milligrams in 1968 you could've just had an egg.A three cent egg.I know 3 cent egg. And I looked at the literature and I and I could not find anything that said death by egg otoxicity. It didn't so everybody that's sitting there thinking oh my gosh, no. I'm not going to do CBD. We were having CBD in our diet. A great Great example, to learn a lot more about this and do a deep dive. Our friend Chris kresser had Will Clyden and the CEO of O-hi, O-hi energetics on and he went into this tremendously. It was so cool. It was just like I just it's crazy that we stopped like, and I as a physician have seen that we are getting sicker as a country. So in 1970, we've got since 1970. We've got more chronic disease, we've got more dementia, we've got more autoimmune disease. coincidence, like we said in the intro, maybe it's at least a contributing factor. And now we have the FDA saying that CBD can be harmful yet it was in our food supply up until 1970.That's nuts, dude.It is nuts. And it doesn't make sense and if you look at mean hemp seed, birds eat seeds, birds consume seeds, they do all kinds of things where they can they take in product, What's the matter? No, I'm just looking at I'm trying to make sure we get through everything.Okay good, but I mean they eat everything and people have been consuming eggs from not just chickens they've been consuming eggs from all different birds on the planet for that long. The fact that we've restricted hemp growth etc has only taken away one of the natural things that birds were eating.If you're if you're really interested in this like I said go to Chris Cressors podcast where he's got Will Clyden on there is really cool wills smart dude Chris is super smart dude. So those guys those guys kick some crazy knowledge.Right?So that is it's weird that we're talking on this episode about CBD causing hepatotoxicity. And we've already shown that the liver's pretty badass, right? It can do a whole lot and we've already shown that the endocannabinoid system is necessary and since 1970, or up until 1970. We are taking in significant amounts of CBD in our dietRight.Weird.It is weird, but it's not so weird when we get down to why everyone's alarmed. So you want to get into a...Now let's go ahead and look at the studies. So that is sort of the phase one of this podcast because now we're going to start geeking out a lot. So I hope I didn't hope I didn't lose everybody with a but you kind of need that background to understand what we're going to talk about next.Sure, you definitely that background.Alright. So what they're talking about is the FDA published this revised consumer update. So this is the consumer update that they put out there for everybody detailing the safety concerns about CBD products. Now, this was based on the studies provided by GW Pharmaceuticals, GW Pharmaceuticals has done multiple different studies looking at different things to get their FDA approval. And I'm going to say right now, that kudos to GW for being the first company to step up and really try and make something for a group of people with intractable seizures have an alternative. Kudos to the FDA for doing their job and looking at the data that was presented to them. What I'm going to do is go next level and say, Well, you didn't look at everything. That's the bottom line here. So I'm not bashing anybody. Let's make let's make certain of this. Sure. So there have been several randomized, controlled and open label trials that studied the effects of epidolex, I'm going to call it epidolex from now on it's just easier, which is a 99% pure oral CBD extract on patients with refractory epilepsy. So this in turn led to the FDA approval for two diseases, dravet syndrome and Lennox-Gestaut syndrome. So if you recognize those names, bless you, because you're dealing with some serious stuff, It's a serious seizure issue. If you don't know those. Count your blessings. It's one of those times to go well, no matter where you're at in life. It's like well, thank goodness that I don't have to Deal with a child that has this because that's, that's a really big deal. These are intractable seizures. So they looked at the data on that. And in these studies, the kicker here is I'm going to say it again, getting back to the lane highway, the patients maintained on their stable drug regimen with a median of three anticonvulsant drugs. That's important. It's super important. Three anticonvulsant drugs. So when we use the analogy of the car on the road, imagine a six lane road. And three of those roads. Three of those lanes are double semis.Yeah, that are closed construction... Or closed, Yeah, that's more likely or closed. So let's talk about that. So when we're talking about three different agents used to control seizures, some of those agents would be and I'm assuming here, but probably Depakote, probably Dilantin, also known as phenytoin, or fosphenytoin, which is seravex. There's a handful of anti seizure medications and through my knowledge, all of them, all of them have been recorded as raising the enzyme levels used by the liver which of course would lead to ALT and AST elevation, showing that the liver is essentially working overtime to long term process these drugs right or wrong?Correct. Correct, which is exactly what the FDA is supposed to do. They're supposed to look at this data and go Okay, so let's just look at the study that they're talking about. So the FDA accumulated this data, and they looked at what GW presented GW presented in isolette of CBD, not a full spectrum. And the dose they ramped up to 20 mg's per kick 20 mg's per kick. What that means is a guy like me would take 1954 milligrams a day.That's a lot more...of CBD isolate. Now I see the effects, beneficial effects of taking KBMD health CBD 15 milligrams twice a day,that's 30 milligrams,that's 30 milligrams.The exact dose of what makes people feel better is very argued because all the data coming out of Israel shows that a lot higher doses, but I'm seeing effects at these doses So let's be real quick let's stop for context. So right now at this intersection what we're what you're saying is with a full spectrum and we said this at the beginning of the podcast that what GW Pharmaceuticals has with epidiolex is a CBD isolate and what they've done...You're saying epidiolex now that's funny. Yeah, whatever it is, Well, because I started with that. Then you told me no, that's not how you say it.I think we should switch it up the whole time. EPA max the way it was edimax. What they did is they were able to establish that almost 2000 milligrams for you would be the ideal dosage however, you...isn't that correct? That's the dosage that they went for or the dosage that they felt was safe, Safe. Okay, I'm sorry. So but but on the upper end of... That was what they were aiming for on everybody. In essence, though, from where you have had beneficial effects, you're talking 60 times that amount, two months worth, is what they are saying the safe level would be in one day where you're finding the beneficial spectrum. So just just in terms of context, full spectrum, CBD, one 60th of the dose that they're saying it's a it's a safe level is really all that you need from our experience.Yeah. Now in GW's defense, let's look at the data. So in dravet syndrome, seizures dropped 39% and in Lennox-Gestaut 42%. So... that's good. So they probably did their homework and said, well, we need to get up that high to actually help that so I don't know anything about that. I'm not a neurologist. That's where it's at. But I'm just saying that when we look at that dose, no average consumer is going to be able to consume that Much CBD in a single day, unless it comes through this 2 full grams a day is more than most take Yes,yeah. Now here's the problem 94% of the people had side effects. Okay 94% at the highest dose compared to 75% placebo, kind of weird. So there's just a huge placebo side effect profile that doesn't get discussed at all.Did they say what it just had a curiosity do they state with the placebo was for the control,They did not stay with the placebo was oh, I take that back. I don't know what they use, but basically they left people on the same medications. So, essentially, let's just look at this and say okay, but the good news is, most of it was not a big deal. Most of it was what the FDA also discussed beyond the liver tests and beyond the drug metabolism. They also said Oh, CBD can cause nausea. It can cause drowsiness. It can cause all these other kind of nuisance things. That's what they're referring to right here. It's interesting though, that have a side effect profile assigned to a placebo that's that exceeds around the 30% range, because that's generally the throwaway number. Yeah. So we've gone twice away from the throwaway number. And they've had they've had reported side effects, which I'm not trying to over draw conclusions here, but it could at least indicate that side effect profiles assigned to CBD in this study probably weren't solely to CBD, Well, you're dealing with one of the highest risk populations you can get your hands on, when I did clinical research and when we would do a moderate to severe Chron's study. The placebo arm would have tons of side effects because the disease is bad. That's what's going on here also. So most was not a big deal, upper respiratory tract infection, somnolence, decreased appetite, diarrhea, blah, blah, blah, blah, blah. But the one that they focused on is the increase in amino transferase concentrations. This once again was a revised consumer update, they put this out to the public and their statement is increase in liver amino transferase concentrations when I just got done explaining what the liver does. Did I ever say amino transferase concentrations? No. I said liver enzymes. right? frickin talk to the public if you're going to release a consumer paper. yeah, liver enzymes. AST ALT. This is hiding behind scientific garbaly goop. It's like you're doing half science half anyway. But but whatever. So a patient show up and they're like, I need you to check my amino transferase concentrations. I'm like, Whoa, why? They Hand me this, this, this news article. Right? This is what we're trying to address right here. So what they found is that in the higher dose, 20 mgs per kg, there was a rise in some patients in three times the level which is significant, so if your normal is 20. You can be 60 if your normal is 40 it can be 120. When patients come into me and it's three times the level it sounds alarming. Do you know what happens when somebody gets hepatitis A acute infection? It's way more than that thousands of times the level when somebody goes into foaming at failure there AST and ALT will go from 40 to 10,000.AST and ALT have risen for almost everyone who's listened here, way more than three times throughout their lifetime multiple times in acute or in very isolated settings. It happens with illness.So getting back to your highway analogy, which I think is really cool analogy. I'm glad you came up with that. Thank you .Getting back to the highway analogy. 80% of them were taking a drug called valproic it matters Depakote Yeah, that matters. That matters a lot.It's when you take these medications, which is why at the beginning of the show, I said you're more likely don't have to worry about it. But if you're on certain medications, keep it in mind. Now that being said at the lower dose didn't see this stuff. So there is a dose dependent usage of the P450 enzyme you can if I give you one drink, or if I give you a bottle of tequila 512 which in my opinion is really one of the tastiest, most fantastic tequilas you can ever get your hands on. It is delicious. It's delicious. I'm gonna I'm gonna digress right here. Oh my God, Tequila 512... Also sponsored by Tequila 512Tt was really good seriously, ummm in every single person with liver test rose.They went back to normal if they decreased the anticonvulsant or decreased the CBD. So either one it went back to normal. So it wasn't number one, it wasn't permanent liver damage. More than likely correct they were able to return back to normal. And number two, it was simply A case of an overwhelmed P450 pathway more more than likely.So you want to get really confusing? Not really but we might as well try. I don't want to but here's what's really interesting, then they kind of get a little geeky. So GW presented their their stuff and then they showed that the P450 in this enzymes and they went into will, the CYP to, 2c19 CYP three a four can inhibit the CYP blah, blah, blah. Those are all just cytochromes people. Those are all just cytochromes It's under the umbrella of P 450. That's how complex this is. Yeah,It is nuts how complex. The highest plasma concentration to CBD occurs within two to three hours after exposure to the Epidolex. With medication, so timing of these medications going to play a role, which actually got me down a weird rabbit hole where i started thinking. We haven't done this much analysis on what happens if you take your Ace inhibiter and you take your cholesterol medicine, timing wise PK analysis on different people and everything. Because when they do these pharmacokinetics, they do it to get the FDA approval, they do it on people that are healthy, that they can understand it. Let's put this into context again, if you're listening to this you've ever taken tagamet. Have you ever thought about when you take your tagamet, you probably only take it whenever you're afraid that you're going to have acid problems, right? Cimetidine?Yeah, guess what? It's also known as a high level p 450 inhibitor if it's over consumed. So I guess what I'm saying here is, there's probably way more alarms being driven over something that yes, is handled by the P 450 system, but is far less invasive or it's much it's a much smaller vehicle on this highway than some of the other things that the alarms are not sounding over.And then surprise surprise after I just got done talking about the liver and the genetic variability and all these other things. When they looked at the pharmacokinetics there was tremendous variation. Hmm. Weird. Yeah. Odd, right? So and anybody that's listening to this that is a, a pharmacist or is a scientist or like Well, yeah, duh. Like I know, duh. But why put out such an alarming statement? Yeah. Without context.Yeah, yeah, you're right. So it for Okay, so it's a little bit of clickbait stuff, right. And so maybe even the journalist who wrote it doesn't understand specifically, the implication, they may have only seen P450, written somewhere turned to a health care provider and said, What is this? Well, that's indicating that things are rising up, they freak out. They write a headline that says CBD causes liver failure. I just learned that from this health care provider. So I'm going to write this piece.Well, that we're going to get into that. The liver failure. This is still just the FDA. Oh, yeah. To the consumer. So I hope that the FDA looks at this and says, You know what? That's right. All that stuff that was just being said it's right. But we didn't have the time to do it. We couldn't sit there put that on paper, we'd lose everybody. I get it. It's quite true. We all we all but we all have a responsibility, much like any doctor to try and explain. You and I have this ability to have this forum to reach hundreds of trillions of people.Yeah. It eflects in our subscriptions on YouTube. They so many trillions of people subscribed, they started his back over to about 200. Yeah, so every time we got trillions, they start back over. Yeah. So So anyways, so what what you're realizing here is exactly what we're talking about. When you put stress on the liver. The liver honks its horn and does a little rise and the lfts goes, Well, hey, guys, maybe not so much. Can we just back off the traffic a little bit and see what's happening here. So additional studies have shown that levels of the anticonvulsant drugs actually caused the daily effects. So now we start wondering that the that the CBD may actually rise some of the anticonvulsants and then you have more side effects from that comes down to the same thing we're talking about how many things do you want to tax your liver, that's the bottom line. To summarize high dose of a pure CBD isolate, not full spectrum, while using a mean of three other anticonvulsants can cause temporary rise in liver tests and affect the metabolism slightly of the anticonvulsant. Of note, it did not happen at lower doses. So one more time, if you are on an anticonvulsant discuss with your doctor and make sure that you stay well below the 2000 milligrams a day. Yep. So this whole thing of Oh We're going to block the P 450 the P450 is So frickin complex, it is nuts. So anything you want to add to that, because I'm going to move on to the thing that I really want to, like kind of make fun of No, not really, I just want to say that I think that the FDA, unfortunately, is a very important and serious organization within our government. And I think that for all of the flack that they take their, unfortunately, with any other entity, there are limitations on what it is that they can do. And I do believe that they try their best to fairly ascertain and address situations as they are presented to them. Regardless of how frustrated that one of this may get is we don't get a result from them. A lot of it is just simply because there's not enough manpower. Oh, absolutely. They get thrown everything think about, think if you're in an organization where you know that 70% of the crap that's out there needs to be pulled off the shelves and you're limited. It's a government organization. These people making these statements are MD's. I'm really limited fortunately, I have well, we have the show where I kind of enjoy looking up some of this stuff. Fortunately, we have some friends of ours that are that work in the nutrition industry that are fantastic at researching articles. And some of that gets gets brought to me I want to make sure that we all get better this is the whole purpose of this.Hundred percent.I want to help the FDA and help GW I want to help the CBD industry. I want to help all of it. But let's just talk about this because something super weird happened. And this is the one that got the most press A Forbes article came out that promoted a mouse study and made the sensational claim that CBD causes liver failure.Yeah, that's kind of what I was referencing earlier. I may steal the thunder but yeah, you're right.Yeah, so this is you're exactly right. In the intro, you said it was clickbait. I really after looking at this study after pulling the study, because how many people read that article are actually going to pull the study.Well is the is the person who wrote this study that well versed in reading studies like that. I mean, that's that's an important thing. I mean, they I think that probably even the author of the article feels like that they are doing a service to the reader, but probably doesn't understand. And if they do, then shame on them, but if they don't, I think that would be a better explanation doesn't fully understand how to read the study and the quality and the qualifications of that study to make a statement like that.Yeah. And you know, this, this could be an arguable point, I'm sure that the person that that wrote this feels very strongly that what they said was right, the bottom line is the goal of this study was to investigate CBD cannabidiol hepatic toxicity, meaning liver issues in an eight week old male mouse. So they they took a group of eight week old male mice, and then they gave them a CBD that they produced. The CBD that they produced and Will Clyden will just jump up and down when he hears this because he decided Is this on Chris Cresser's podcast. The CBD that they produced was used to extract using hexane, which is a molecule that is known to be hepatotoxic. Yeah, you're not supposed to have heaxane. Don't do that! Will Clyden talked about the fact that if you find a CBD with an outrageously high amount of of CB, if you find a full spectrum CBD with an outrageously high amount of CBD more so and the price ranges, okay? Because what they did is they extracted that with hexane in a cheap way and threw it in their bottle and said, there you go. Now you can check that's got 10,000 milligrams of CBD or whatever. And it's really interesting because there's so much going on in the industry like this. So this particular study out of the University of Arkansas, took the CBD, or they made their own CBD using hexane which is a hepatotoxic in itself and in their certificate of analysis. It was there and then they gave it to these mice. Second thing neatI don't even know there has to be a second but we can hear it. Because I mean seriously, that's, that's like saying, I know your stomach hurts. You should take this Pepto bismol. And then I don't tell you that I've broken up some glass shards and have you drink it and you're like i'm bleeding now! What's going on? I'm like, I don't know. Yeah, but you only paid half the price.I made it myself.Which, by the way, that last batch of propophol that you did in your bathtub is working phenomenally. I'm sure it is. Now we do not make propophol in our bathtubs.Alright, so the second issue. If we have any mice that are subscribers to our show, or listening, I would like you to have your children removed from the room at this moment. Because they took these poor mice, and they gavaged to them. Would you mind defining what gavaged is? I think it's when you kind of force feed somebody I don't think it's willing. That's your I think gavaged something you kind of threw one at me there I think to gavaged someone you basically introduce a funnel to the esophagus and well you kind of get after it, don't you? Yes, I'm currently gavaging my mic right now trying to figure it out. I just undid everything. You're gavaging our ears with your, your microphone adjustments?All right, so gavage is they forcibly give these mice?The CBD extract? Yeah, I don't think it's comfortable nor pleasant.No typically through a tube feeding or down the throat to the stomach is how they generally gavage things. A quick side note, now because I'm now all of a sudden I feel like I'm living in a glass house when I was an undergraduate student. I actually did my first surgery on a rat and we took out their adrenal glands. And I'm just saying that so I don't want to sit there and pretend like I'm not done mean things to an animal. But that was when I knew immediately I could not be a bench researcher. I did not like that. At all, now I was like, I need to, I want to heal. I want to heal. I don't want to hurt these animals, but it's it's a whole separate discussion. So anyways, so they gavage these animals with different doses, and it's really interesting. Now in what they call their defense, they call it allometric dosing, which means they're trying to get the body weight to human weight ratio appropriate. I've read some rebuttals of this article where it is a joke, you just can't do that. And when I read vitamin weed Michelle Ross? Michelle Ross, when I read vitamin weed she dis... she specifically discusses why research on CBD versus mice is very difficult to do because the weight basing the endocannabinoid system is different, all these other things. So allometric dosing being said, assuming that they're saying it's right, so the dose would be the equivalent of what they gave and What a human would give So I'm doing the allometric dosing, which I think is actually higher than what it actually is separate thing. They took mice and they gavaged them with zero milligrams of hexane derived CBD 246 milligrams per kilogram 738 milligrams per kilogram or 2460 milligrams per kilogram of dirty CBD. It doesn't make sense dirty CBD isolate. So for instance, in a horrible alternate universe where humans are now the test subjects and we have large mice which are running tests on us, and they decided to gavage me with the same thing. That would be the equivalent at the highest dose of 241,080 milligrams of hexane derived CBD isolate. I'm not even sure what the hexane would do it 240,000 milligrams 242,000 milligrams.No I mean that being the more or less than now at this point, it's just an additive. It's just I mean it's it's not an excipient It's a straight up additive. That would not make sense at all. Oh, it's crazy.It's poison.This article came out in Forbes and said CBD causes hepatotoxicity. Also hexane causes hepatotoxicity.It is nuts. Alright, spoiler alert. The mice suffered hepatic toxicity and death at the highest dose. Shocking... You know what? I also hear it's bad to have breakfast cereal with not milk but drain-o. Just something that I'm gonna go out on a whim. Don't think you're supposed to do that. It just doesn't make sense. It's It's It's not. That is not an apples to apples comparison if you're talking Okay, so we talked about it earlier. reputable CBD source there is no reputable CBD producer that's going to have and Will special shout out to you it's going to have hexane as a byproduct or an excipient in their full spectrum COA approved which is also why KBMD Health with powered by olyxenol hundred percent is does not have that. I mean they do co2 extraction, which is the important thing which is a reason why we partnered with them to make that product. So we are the one out of the 23 or 24 that is the safe and trusted COA back no hexane etc etc. Doing this study is not an apples to apples comparison on what would happen because who knows? Who Okay, I don't get it because GW we already did that study. They determined that 20 Meg's per kg which is still a shit ton. It's a lot. It's a lot. Yeahis the safe maximum dose. These guys went times it by 100.Yeah, they did.And see what happens? Yeah, it's it's a bad it's a bad comparison. I mean, yeah, honestly, if you wanted to find out if CBD plus hexane causes liver toxicity at a ridiculous amount, top to bottom, then that's a great study outside of that, since nobody does it, I would say it's a bad study. Speaking of road, that's a road to nowhere.Yeah. And so study like this, uh, like you had mentioned is essentially it's not science. It's clickbait. Yeah. And right now that that author, that journalist is just kind of laughing. He's like, I know, and now you're bringing it up, and I'm going to get another whatever, because that's what people are trying to do. They're trying to get attention at this point.So at that point, good for you, you got to click but I would be truly interested if possibly that particular journalists would say, you know what, I didn't fully understand it. I mean, that's okay. Let's look reading studies, right? There's there's a study to reading studies. I mean, we heard that we heard the breakdown that kresser did on Joe Rogan is he Twice had to address his approach to completely different topic about the the plant based diet and then how he had to re approach that with the rebuttal. All that just simply to say, there is a science to reading studies and being really good at understanding what is and is not applicable and then how to find studies that you can compare to each other for good meta analyses. So what we're doing right now is I'm telling you that maybe sometimes there aren't studies, but my anecdotal evidence, I have a busy practice, you hear the patients, we hear them talk I listen to them, when they say that doesn't work. I go, Okay, I'm not publishing it. I don't have time to do that. I wish I did. If I published everything that we're gathering data on, if we're looking at, you know, just so many different things, CBD is just one of them. We've got I love I'm a huge fan of brain.FM for the ability to use sound to change your mood. I Would love to they're unpublished, a lot of studies on stuff like that. There's, there's tons of stuff. So when people go, oh, the studies aren't out there, there is something to be said about the Socratic method, or I'm sorry, the paternalistic method, the way that medicine used to be where the guy in front of you that saw thousands of patients, this is the method that he has. You see me scope, I mean, there's a difference in scope techniques.So they, although some may even still say it qualifies as anecdotal, I will say that there's objective data in both in a scope, somebody can't just come, anybody can come to you say I feel better. Anybody can even if they don't mean it. But they can't make the disease disappear from the imaging that we see in their colonoscopy, or the the mucosal samples that you take. And that's something that's completely objective data. That we see. So those are the everyday results that we see from these types of applications where you just, look it's not made up whenever we okay full pleasure when we first started looking at CBD, I thought was bullshit. Who you looking at?Just anybody who's out there. But when we first started talking about it, I didn't believe it. I was like, man, let's see, because we've been down this road before but we tried new, new without throwing a bunch of things under the bus. We tried new or innovative different things and high hopes. And unfortunately, low expectations and the expectations get met and the hopes are never never realized. The opposite for me personally occurred with CBD over the last three and a half years. And that is it actually stinking works.Dude, I knew that we were onto something with Atrantil, because after we did the initial studies, everybody came back and said, I want more. I knew that I was onto something or I was not on something. I knew that CBD had a viable place in my practice, because I bought and the story goes all the way back which is why we work with which is why it's powered by elyxenol right now, when we went to paleo FX, and I ordered a couple cases and I just gave them away to patients. That was not cheap. Not because I was sitting there trying to be altruistic, not because I was doing charity. I'm like, I don't know. I didn't. And I told everybody, I don't have a clue. I haven't even looked at this yet. All I know is try this. Tell me what happens. And when about 80% of them came back said I want more. And I went, Okay, we're onto something. And that's when I took my clothes off the deep dive into the science and went, holy cow. Yeah,this is crazyUp until that point, I just didn't know there was a whole lot to it. I mean, it really didn't. And then the fact is, oh, and to clarify, it's not like Brown just handed out CBD to just anybody who came to the clinic. You literally just like we did with Atrantil you found very diseased patients to say and who had gone through a gamut of different pharmaceuticals and weren't finding relief, and suddenly they're like, this is working for me. Tell me more about it. And I was, I was blown away.So let's talk a little bit. So we're I'm over here going well studies I haven't published and everything. Let's talk about a few studies. So I've got a Mendeley account, I know how to look at PubMed. I know how to get a Google Scholar, I just want to talk about a couple studies have come out recently. And let's kind of compare it and see if it still makes people concerned that they're going to die of liver failure.Sure. Alright. So in the Journal of Clinical Pharmacology published in 2019, the this was actually a study, also sponsored by GW Pharmaceuticals, as part of the process of getting the FDA approval that the FDA did not reference the best I can tell they did not reference this. This is way more complex and it gets super cool, because what they're looking at is the pharmacokinetics or how CBD is actually metabolized by that beautiful genius called a liver. In high doses in people with liver disease. Yeah, they went through the trouble to take high doses of CBD and give it to people People that did not have liver disease had mild liver disease moderate and severe. This was ballsy to say the least, because using a product like this in somebody with liver disease is is risky. This thing could backfire and it could shut down the whole process. Here's what's nuts, the pharmacologic and safety of a single oral dose of 200 milligrams of epidolex, which is the CBD isolate. They were assessed in subjects they had eight people with moderate or with mild disease, six people with moderate and eight people with severe and then they had this collection of normal people. Blood samples were collected to check for the pharmacokinetics This is how drugs are looked at. They give you a drug and then they check your levels. Basically, the blood concentration was higher in the hepatic impairment and they describe it in nanograms. So the nanogram comparison is that it's a little bit higher in those with severe hepatic impairment. But this is what's nuts there was no increase in adverse reactions. There was no change in blood levels. So basically, the only adverse reaction that they found was a little bit of diarrhea. And it all happened in the mild hepatic impairment. So the FDA had mentioned Oh, studies have shown that it causes diarrhea. What was really funny about
Raphael Mechoulam, an Israeli organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, remembers the letdown after his groundbreaking discoveries surrounding the structure of the cannabis compounds CBD and THC in 1963 and 1964, followed by clinical tests with CBD published in 1980. GO TO THIS CTFO SITE NOW “Not much happened,” Mechoulam said, noting that it would take more than 30 years before his clinical work on using CBD, or cannabidiol, to treat epilepsy became widely accepted. Greenwich Biosciences, which is owned by GW Pharmaceuticals, was able to develop the first cannabis-derived drug that built on Mechoulam’s research. The drug, Epidiolex, treats seizures associated with two rare forms of epilepsy and was approved by the FDA only last year. But even as his work laid the foundation for the modern cannabis industry and for understanding how cannabis interacts with the human body, a white whale eluded research: cannabis acids, which are compounds that are produced in the plant when it is alive and may be more potent than their better-known derivatives, such as CBD and THC. That changed on Monday, when Mechoulam and a group of researchers announced at a medical cannabis conference in Pasadena, California, that they have developed a process for creating synthetic, stable acids that are found within the plant, and that the synthetic acids, which include acid versions of CBD and THC, are now available for licensing to companies for drug development. The discovery paves the way for drug companies to potentially develop new drugs based on the acids for a variety of health issues such as psoriasis, arthritis, anxiety and inflammatory bowel disease. --- Send in a voice message: https://anchor.fm/bhsales/message
Where does creativity fit into compliance? In more places than you think. Problem-solving, accountability, communication, and connection - they all take creativity. Join Tom Fox and Ronnie Feldman on Creativity and Compliance, part of the Compliance Podcast Network. In this show, we’ll be exploring how creativity affects the world of compliance - the ways we use it, and the surprising impacts it can have on the work we do every day. From ethics to leadership, problem-solving to training - creativity permeates what we do as compliance professionals. In this podcast we have a special quest, Angelique Lee-Rowley, CCO of GW Pharmaceuticals who visits on the use some of the creative programming the company have rolled out this past year. Some of the highlights include:What drew Lee-Rowley to the project?What were some of her hesitancies about utilizing a comedic approach?It's not about the funny, it's about being interesting and provocativeIt's about being empathetic and on the side of employeesIt's about being provocative so they don't just snooze their way through trainingI'm not a fan of scare tactics.How has the company utilized the programming thus far?Live trainingE-LearningPaired with other trainingCommercialsHow has the programming been received and how has it helped your compliance efforts?What were some of the reactions from the employees?What are some of the lessons have you learned?Don't be afraid to try new thingsDon't be too precious about finding the perfect solution. Engage employees with variety and surprise...keep people on their toes.Resources: Ronnie Feldman (LinkedIn) Learnings & Entertainments (LinkedIn) Ronnie Feldman (Twitter) Learnings & Entertainments (Website) 60-Second Communication & Awareness Shorts – A variety of short, customizable, quick-hitter “commercials” including songs & jingles, video shorts, newsletter graphics & Gifs, and more. Promote integrity, compliance, the Code, the helpline and the E&C team as helpful advisors and coaches. Workplace Tonight Show! Micro-learning – a library of 1-10-minute trainings and communications wrapped in the style of a late-night variety show, that explains corporate risk topics and why employees should care. Custom Live & Digital Programing – We’ll develop programming that fits your culture and balances the seriousness of the subject matter with a more engaging delivery. See also, Ronnie’s article on CCI, How Corporations Can Use Comedy and Creativity to Enhance Risk Training
Understanding the Pharmacology of Cannabis. Dr. Ethan Russo speaks about the science of Cannabis, Cannabinoids, and Terpenes at the Cannabis Hemp Conference and Expo (CHCE). Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human Endocannabinoid system. Previously, from 2003-2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® for pain and MS, and initial studies of Epidiolex® for intractable epilepsy. He graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington. He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany. He has consulted or lectured on these topics in more than 30 US states and 30 countries. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/oilycadre/message Support this podcast: https://anchor.fm/oilycadre/support
The cannabis extract CBD or cannabidiol is legal in many countries, and now it's finding its way into everything from soaps to cosmetics. But is it just a fad, and are its health claims bogus? Manuela Saragosa asks Harry Sumnall, professor in substance use at Liverpool John Moores University, whether it is true that CBD is not a psychoactive substance - unlike the more infamous cannabis extract THC. And is it true that it can be used to treat the symptoms of Alzheimer's, anxiety and cancer amongst others? Meanwhile Katie Prescott explores the booming market for CBD products. She speaks to Jim McCormick, president of cannabis brand Ignite International; Eveline van Keymeulen, head of life sciences regulations at law firm Allen & Overy; Alex Brooks of financial services firm Canaccord Genuity; and Chris Tovey of GW Pharmaceuticals. (Picture: Cannabis leaf; Credit: digihelion/Getty Images)
This Week In Marijuana Business News for the week ended May 10, 2019, with host Nick Thomas. Headlines include: 5 key takeaways from MJBizDaily’s European Cannabis Symposium CBD giant CV Sciences reports $9 million loss in first quarter Cannabis firm Cronos Group misses on revenue, reports wider Q1 loss Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement Chart: Florida medical cannabis market surges ahead, with five companies dominating Texas House OKs second bill to expand medical marijuana qualifying conditions Alabama Senate moves limited medical marijuana program bill forward Ohio panel endorses anxiety, autism as conditions for medical marijuana use Cannabis business win/loss scorecard in Golden State’s legislative session Schumer to reintroduce federal cannabis reform bill Netherlands prepares legal recreational cannabis cultivation experiment Most state attorneys general back cannabis banking reform; treasurers warming What can cannabis learn from the tech industry? Q&A with ex-Yahoo CEO and current Caliva chair Carol Bartz Subscribe to both of our podcasts on iTunes, Stitcher and here on our site!
Dr .Ethan Russo, is a board-certified neurologist, psychopharmacology researcher, and the director of the Institute For Cannabis and Cannabinoid Research. He is a former Senior Medical Advisor to GW Pharmaceuticals, a biotechnology company that specializes in developing different ways of targeting the endocannabinoid system for therapeutic benefit.He is currently on the board of Director of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines. Widely published author in many scientific journals, and contributor and editor of several booksDo we really how much about the endocannabinoid system (ECS) at all and do the terpenes in cannabis matter? We ask Dr Russo just that and more in this episode. We discuss how without clinical research to support the cannabis movement we don't have a foundation for the future of this plant medically. The cannabis prohibition greatly affected the development of this much needed research but with new evidence emerging supporting the Entourage effect we talk through what this mean for us today. https://www.phytecs.com/wp-content/uploads/2015/02/IntroductionECS.pdf https://www.amazon.com/Cannabis-Pariah-Prescription-Ethan-Russo/dp/0789023997 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200872/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334252/ http://www.phytecs.com/team/erusso/ To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkhDisclaimer: The information presented in this podcast is for educational purposes only, and is not intented to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.
In this week’s episode we dive deeper into understanding medical cannabis. Does it really cure what ails you or is this all smoke and mirrors? Fact: Tetrahydrocannabinolic acid (THCA), the raw acid form of THC, is the most abundant non-psychoactive cannabinoid found in cannabis. What is the endocannabinoid system (ECS)? a biological system composed of endocannabinoids first discovered in the late 1980’s promotes homeostasis at every level of biological life all vertebrates are known to have receptors have been found all over the body and interact with the major systems found within our body. ECS is Made Up of 3 Parts Endocannabinoids Receptors in the nervous system and around the body that endocannabinoids and cannabinoids bond with Enzymes that help break down endocannabinoids and cannabinoids Functions of the Endocannabinoid System Research shows it is an overall body modulating system, doing its best to get our body to balance and keep it there. Memory Appetite Digestion Mood Inflammation Energy Storage and Metabolism Stress Response Immune Function Female Reproduction Autonomic Nervous System Analgesia Thermoregulation Sleep Physical Exercise May play a dual role on the regulation of tumor generation and progression Receptors Two Known receptors in our body that interact either with internal or external cannabinoids are the CB1 and CB2. Cannabinoid - The CB1 receptor is expressed mainly in the brain and nerves of the spinal cord (central nervous system or "CNS"), but also in the lungs, liver and kidneys. Endocannabinoid - The CB2 receptor is expressed mainly in the peripheral nervous system (nerves in your extremities), the digestive system, and specialized cells in the immune system Risks of Self Dosing with Recreational Cannabis Not seeking recommendation on dosing from a medical professional may be problematic to the individual. Drug to drug interactions Self-misdiagnosis Correct dosage Cannabis and Inflammation THCA tinctures infused with coconut oil or grapeseed oil THCA is non-psychoactive until introduced to heat Very effective in maintaining a healthy inflammation response Cannabis and Sleep D. Anderson has said, "Less than six hours, and more than nine hours of sleep is bad." Often poor sleep is the root cause of issues like depression and anxiety Indica strain of cannabis plant is good for sleep - take one hour before bed L-Tryptophan is also a good option to aid sleep Ratios You will hear 2:1 ratio, 4:1 ratio, 8:1 ratio, 16:1 ratio. This can be CBD:THC or THC:CBD. Always ask what that first number is. Don't be afraid to ask the question, “what is the first number? Considerations When Using Medical Cannabis Avoid synthetic versions due to side effects Be educated before talking to your Doctor Use reputable dispensaries who create clean cannabis and provide test results May be used as preventative wellness medicine The Sacred Plant John Malanca is host and advocate, along side Founder Manny Goldman Provide education and insights from the Patient, Physician, Caregivers, Researchers, and more perspective and experiences with Cannabis as medicine Helping break down the stigmas, understand the research, and using this information to continue advocacy United Patients Group Founded by John and Corinne Malanca to fill the information void surrounding medical cannabis. Don't sell products - patient advocacy - strictly education and information. Teach local, state, international governments, as well as local, state and international medical institutions about medical cannabis. All courses are CME (continuing medical education) approved by the American Medical Association. Deeper Dive Resources John Malanca: https://www.linkedin.com/in/john-malanca-7807956b https://unitedpatientsgroup.com/about-cancer-and-medical-cannabis/ United Patients Group: https://unitedpatientsgroup.com/ https://www.facebook.com/UnitedPatientsGroup/ The Sacred Plant: http://thesacredplant.online/t?orid=614242&opid=796&sid=D18L1_podcast https://www.facebook.com/oursacredplant/ The History of Cannabis as a Medicine: http://www.scielo.br/scielo.php?pid=S1516-44462006000200015&script=sci_arttext&tlng=pt Endocannabinoid System: https://en.wikipedia.org/wiki/Endocannabinoid_system Cannabinoids: https://en.wikipedia.org/wiki/Cannabinoid Cash Hyde Foundation: http://www.cashhydefoundation.org/cashys-story GW Pharmaceuticals: https://www.gwpharm.com/ Hemp: https://en.wikipedia.org/wiki/Hemp Laws By State: https://unitedpatientsgroup.com/Medical-Marijuana-Laws-By-State Studies: Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes - Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/ The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans - The endocannabinoid system has been recently recognized as an important modulatory system in the function of brain, endocrine, and immune tissues. It appears to play a very important regulatory role in the secretion of hormones related to reproductive functions and response to stress. https://www.ncbi.nlm.nih.gov/pubmed/17369778 Endocannabinoid system acts as a regulator of immune homeostasis in the gut - Study unveils a role for the endocannabinoid system in maintaining immune homeostasis in the gut/pancreas and reveals a conversation between the nervous and immune systems using distinct receptors. https://www.pnas.org/content/early/2017/04/18/1612177114.long The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities - Recent studies have intriguingly suggested the existence of a functional ECS in the skin and implicated it in various biological processes (e.g. proliferation, growth, differentiation, apoptosis and cytokine, mediator or hormone production of various cell types of the skin and appendages, such as the hair follicle and sebaceous gland). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757311/ Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans - The endocannabinoid system was subject to cancer-associated regulations to an extent that led to measurable changes in circulating endocannabinoid levels, emphasizing the importance of the endocannabinoid system in the pathophysiology of cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278301/ Endocannabinoid and ceramide levels are altered in patients with colorectal cancer - Endocannabinoids and ceramides have demonstrated growth inhibition, cell death induction and pro-apoptotic activity in cancer research. In the present study, we describe the profiles of two major endocannabinoids, ceramides, free fatty acids and relevant metabolic enzymes in 47 pairs of human colorectal cancer tissues and adjacent non-tumor tissues. https://www.ncbi.nlm.nih.gov/pubmed/25975960 Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa - Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. https://academic.oup.com/ajcn/article/101/2/262/4494381 Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids - Cannabis and/or cannabinoids protect the gastric mucosa against noxious challenge with non-steroidal anti-inflammatory drugs, ethanol as well as against stress-induced mucosal damage. Cannabis/cannabinoids might protect the gastric mucosa by virtue of its antisecretory, antioxidant, anti-inflammatory, and vasodilator properties. https://www.sciencedirect.com/science/article/pii/S1995764516300712 The use of cannabinoids as anticancer agents - In conclusion there exist solid scientific evidences supporting that cannabinoids exhibit a remarkable anticancer activity in preclinical models of cancer. Since these agents also show an acceptable safety profile, clinical studies aimed at testing them as single agents or in combinational therapies are urgently needed. Results from these studies are essential to clarify whether cannabinoids (and specifically cannabinoid-based medicines) could be helpful in the fight of cancer. https://www.sciencedirect.com/science/article/pii/S0278584615001190
In this week’s episode we dive deeper into understanding medical cannabis. Does it really cure what ails you or is this all smoke and mirrors? Fact: Tetrahydrocannabinolic acid (THCA), the raw acid form of THC, is the most abundant non-psychoactive cannabinoid found in cannabis. What is the endocannabinoid system (ECS)? a biological system composed of endocannabinoids first discovered in the late 1980’s promotes homeostasis at every level of biological life all vertebrates are known to have receptors have been found all over the body and interact with the major systems found within our body. ECS is Made Up of 3 Parts Endocannabinoids Receptors in the nervous system and around the body that endocannabinoids and cannabinoids bond with Enzymes that help break down endocannabinoids and cannabinoids Functions of the Endocannabinoid System Research shows it is an overall body modulating system, doing its best to get our body to balance and keep it there. Memory Appetite Digestion Mood Inflammation Energy Storage and Metabolism Stress Response Immune Function Female Reproduction Autonomic Nervous System Analgesia Thermoregulation Sleep Physical Exercise May play a dual role on the regulation of tumor generation and progression Receptors Two Known receptors in our body that interact either with internal or external cannabinoids are the CB1 and CB2. Cannabinoid - The CB1 receptor is expressed mainly in the brain and nerves of the spinal cord (central nervous system or "CNS"), but also in the lungs, liver and kidneys. Endocannabinoid - The CB2 receptor is expressed mainly in the peripheral nervous system (nerves in your extremities), the digestive system, and specialized cells in the immune system Risks of Self Dosing with Recreational Cannabis Not seeking recommendation on dosing from a medical professional may be problematic to the individual. Drug to drug interactions Self-misdiagnosis Correct dosage Cannabis and Inflammation THCA tinctures infused with coconut oil or grapeseed oil THCA is non-psychoactive until introduced to heat Very effective in maintaining a healthy inflammation response Cannabis and Sleep D. Anderson has said, "Less than six hours, and more than nine hours of sleep is bad." Often poor sleep is the root cause of issues like depression and anxiety Indica strain of cannabis plant is good for sleep - take one hour before bed L-Tryptophan is also a good option to aid sleep Ratios You will hear 2:1 ratio, 4:1 ratio, 8:1 ratio, 16:1 ratio. This can be CBD:THC or THC:CBD. Always ask what that first number is. Don't be afraid to ask the question, “what is the first number? Considerations When Using Medical Cannabis Avoid synthetic versions due to side effects Be educated before talking to your Doctor Use reputable dispensaries who create clean cannabis and provide test results May be used as preventative wellness medicine The Sacred Plant John Malanca is host and advocate, along side Founder Manny Goldman Provide education and insights from the Patient, Physician, Caregivers, Researchers, and more perspective and experiences with Cannabis as medicine Helping break down the stigmas, understand the research, and using this information to continue advocacy United Patients Group Founded by John and Corinne Malanca to fill the information void surrounding medical cannabis. Don't sell products - patient advocacy - strictly education and information. Teach local, state, international governments, as well as local, state and international medical institutions about medical cannabis. All courses are CME (continuing medical education) approved by the American Medical Association. Deeper Dive Resources John Malanca: https://www.linkedin.com/in/john-malanca-7807956b https://unitedpatientsgroup.com/about-cancer-and-medical-cannabis/ United Patients Group: https://unitedpatientsgroup.com/ https://www.facebook.com/UnitedPatientsGroup/ The Sacred Plant: http://thesacredplant.online/t?orid=614242&opid=796&sid=D18L1_podcast https://www.facebook.com/oursacredplant/ The History of Cannabis as a Medicine: http://www.scielo.br/scielo.php?pid=S1516-44462006000200015&script=sci_arttext&tlng=pt Endocannabinoid System: https://en.wikipedia.org/wiki/Endocannabinoid_system Cannabinoids: https://en.wikipedia.org/wiki/Cannabinoid Cash Hyde Foundation: http://www.cashhydefoundation.org/cashys-story GW Pharmaceuticals: https://www.gwpharm.com/ Hemp: https://en.wikipedia.org/wiki/Hemp Laws By State: https://unitedpatientsgroup.com/Medical-Marijuana-Laws-By-State Studies: Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes - Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/ The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans - The endocannabinoid system has been recently recognized as an important modulatory system in the function of brain, endocrine, and immune tissues. It appears to play a very important regulatory role in the secretion of hormones related to reproductive functions and response to stress. https://www.ncbi.nlm.nih.gov/pubmed/17369778 Endocannabinoid system acts as a regulator of immune homeostasis in the gut - Study unveils a role for the endocannabinoid system in maintaining immune homeostasis in the gut/pancreas and reveals a conversation between the nervous and immune systems using distinct receptors. https://www.pnas.org/content/early/2017/04/18/1612177114.long The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities - Recent studies have intriguingly suggested the existence of a functional ECS in the skin and implicated it in various biological processes (e.g. proliferation, growth, differentiation, apoptosis and cytokine, mediator or hormone production of various cell types of the skin and appendages, such as the hair follicle and sebaceous gland). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757311/ Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans - The endocannabinoid system was subject to cancer-associated regulations to an extent that led to measurable changes in circulating endocannabinoid levels, emphasizing the importance of the endocannabinoid system in the pathophysiology of cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278301/ Endocannabinoid and ceramide levels are altered in patients with colorectal cancer - Endocannabinoids and ceramides have demonstrated growth inhibition, cell death induction and pro-apoptotic activity in cancer research. In the present study, we describe the profiles of two major endocannabinoids, ceramides, free fatty acids and relevant metabolic enzymes in 47 pairs of human colorectal cancer tissues and adjacent non-tumor tissues. https://www.ncbi.nlm.nih.gov/pubmed/25975960 Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa - Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. https://academic.oup.com/ajcn/article/101/2/262/4494381 Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids - Cannabis and/or cannabinoids protect the gastric mucosa against noxious challenge with non-steroidal anti-inflammatory drugs, ethanol as well as against stress-induced mucosal damage. Cannabis/cannabinoids might protect the gastric mucosa by virtue of its antisecretory, antioxidant, anti-inflammatory, and vasodilator properties. https://www.sciencedirect.com/science/article/pii/S1995764516300712 The use of cannabinoids as anticancer agents - In conclusion there exist solid scientific evidences supporting that cannabinoids exhibit a remarkable anticancer activity in preclinical models of cancer. Since these agents also show an acceptable safety profile, clinical studies aimed at testing them as single agents or in combinational therapies are urgently needed. Results from these studies are essential to clarify whether cannabinoids (and specifically cannabinoid-based medicines) could be helpful in the fight of cancer. https://www.sciencedirect.com/science/article/pii/S0278584615001190
Matt Chiodi, Chief Information Security Officer at RedLock, on China's hack into U.S companies, and what companies should be doing. Edward Hertzman, Founder and President of Sourcing Journal, on the impact of tariffs on textiles and the supply chain, and how Amazon is changing the apparel landscape. Jeremy Keehn, Bloomberg editor, on China using a tiny chip in a hack that infiltrated US companies, including Apple and Amazon. Justin Gover, CEO of GW Pharmaceuticals, on their FDA-approved cannabis drug Epidiolex receiving the lowest drug restriction by the DEA, and what's next in the company pipeline.
Epidolex CBD - Friend or Foe? You Decide. Written By Mike Robinson ~ Cannabis Heals Cancer Survivor ~ International Cannabinoid Cancer Research Institutes/Domestic Animal Research Ctr. Co-Founder/Director We all knew the pharmaceutical industry would step into the world of Medicinal Cannabis and take over with a bang, but we did not expect it to happen with a whirlwind of professionals voicing concerns globally. Questions are looming about dosing, increased seizures in patients, a death in the trials to seizures, and even other epilepsy drugs that combined with this one can be life-threatening. Even the likes of Professor Raphael Mechoulam, the Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel who first isolated and identified THC in the 1960's and discovered the Endocannabinoid System 3 decades later, created panels and meeting from across the Atlantic to here in California this coming week, and will address this at the huge CannX conference he hosts every year in his country. Dr. David Bearman of the American Academy of Cannabinoid Medicine has been invited to give his input there. Liz Minda, cannabis advocate and nurse, the mother of Jadyn with Severe Intractable Epilepsy stated, "Epidiolex was the last pharmaceutical we tried and it failed for seizure cessation. Full spectrum cannabis oil stopped seizures and gave her a brighter cognitive and physical ability every day. The best Leap of Faith I have ever taken. Currently, for the last 12 months Jadyn is on CBD only, not Epidiolex!" I was part of her compassion crew that helped wean Jadyn from GW's CBD to the plant - and it's nowhere near the same. It seems that many are quite upset at the fact that Pharmaceutical CBD will be compared to Hemp derived and Cannabis Flower derived CBD products that do not cause the problems nor carry side effect warnings such as GW Pharmaceuticals has been forced to put on it's product by the F.D.A., take a look - you decide. Would you take this drug as a replacement for pharmaceuticals? Would you consider it a 'good representation' of the 'dangers' of Cannabis products? How many of us want these type of warnings blasted out on TV advertisements for the drug creating a new "Reefer Madness 2019" in which people that are considering cannabis as medicine will then change their mind. Approval of a drug, or a way to scare consumers away? WARNINGS AND PRECAUTIONS (From FDA Website) Hepatocellular Injury: EPIDIOLEX can cause transaminase elevations. (LIVER DAMAGE) Concomitant use of valproate and higher doses of EPIDIOLEX increase the risk of transaminase elevations. See Full Prescribing Information for serum transaminase and bilirubin monitoring recommendations. (5.1) Somnolence and Sedation: Monitor for somnolence and sedation and advise patients not to drive or operate machinery until they have gained sufficient experience on EPIDIOLEX. (5.2) Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and thoughts. (5.3) Hypersenstivity Reactions: Advise patients to seek immediate medical care.(5.4) Withdrawal of Antiepileptic Drugs: EPIDIOLEX should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus. LET ME INTERRUPT: Status epilepticus (which kills nearly 50,000 people per year, Olympian "FloJo" died of seizures/status in her sleep) is caused by discontinuing a cannabis product? Since when does stopping a cannabis created product CAUSE the problem you're treating? Since when is CBD addictive? Never... but when does a pharmaceutical cause us problems? When are they addictive? Daily. (5.5) ADVERSE REACTIONS: The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) are: somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. (6.1). (ALL of the above will be 'disclaimed' in Television and print advertisements, and quickly the world will liken CBD itself to Big Pharma's version) USE IN SPECIFIC POPULATIONS: Pregnancy: Based on animal data, may cause fetal harm. I'm not sure how you're deciding on this one but for me this is quite obvious. It's not CBD that does these things to people, it's pharmaceuticals. It's not the plant that would ever cause these problems - it's pharmaceuticals. Leave it to that industry to dirty the name of a plant that saves and changes lives daily. We as a movement to legalize nature should not step back and watch, once again, as Big Pharma creates a cannabis medicine and it's scheduled way down the list like Marinol (Synthetic THC) which has been a Schedule 3 since 1985. Epidolex proposal is at Schedule 4. How possibly can our country's leadership sleep at night with the plant these drugs came from still schedule 1 while our citizens fight death defying illness and fight to gain access to a plant to become "Illegally Healed"? Guest Bio and Social Media Links: Mike Robinson, the Director of Communications for The American Academy of Cannabinoid Medicine, is a Multiple Cancer survivor that's used cannabis oils extensively as well for Severe epilepsy, Chronic Lyme Disease, PTSD, and in pain management. Over the last 5 years Mike has shared his journey and analytics on cannabinoid medicine research globally while assisting patients and clinicians during his own journey. The co-founder and Director of the International Cannabinoid Cancer Research Institutes, joined by some of the top research doctors and experts across the globe, Robinson brings vision to the future of Cannabis as Medicine. As well, he's founded The Domestic Animal Research Center that focuses on Cannabinoid Medicine for all vertebrates, including livestock and zoo animals. An extensive background includes being an effective leader of a large Cannabis compassion program providing to the disadvantaged that treated countless medicinal cannabis consumers with various alternative protocol treatments, Robinson is also a published journalist and research analyst. Historically a former Registered Ca. State Lobbyist 1997 and Pro-bono non-attorney representative for children with disabilities nationwide for over 2 decades, a former member of the Board of Directors for Big Brothers and Sisters, the founder and board member of multiple nonprofits that advocate/advocated for the rights of disabled children, and most important, the Dad of one of his former compassion patients that he's taken on as his own daughter. https://www.mikesmedicines.com/medical-marijuana/the-cannabis-lovestory/ Mike Robinson Linkedin Credits: Producer: Barry Krauss Sponsor: Soil to the Oil Advisory and Media Podcast Links: CLICK HERE TO SUBSCRIBE ON ITUNES AND LEAVE A REVIEW! Click Here For Podcast Website Join and Like our Facebook Page!
Can robots do this? Zoom in on candles to get context and insight. $gwph $study
In this episode #8 of the MELLOW RIOT PODCAST, the host Mike Mattarocci does a solo podcast as a trial run for more to come in the future, potentially. There are several articles reviewed in this VLOG. The first one was regarding doctors who are just now starting to feel comfortable recommending marijuana, but only for issues with nausea and appetite. They claim to not have enough research to direct people to cannabis for all of it's other amazing cancer fighting benefits - maybe big pharma is still breathing down their necks too heavily?The second article detailed how 60+ holistic doctors have all "committed suicide" in the last 2 years. Strangely, they all have 2-3 similar traits in common - they all prescribe either Rick Simpson Oil to their patients, or they recommend GcMaf, which is a very effective (and controversial) tool that battles cancer and many other diseases.The final commentary came from an article discussing the new patented drug EPIDIOLEX, which has cbd oil in it, as well as trace elements of a synthetic drug. This enables GW Pharmaceuticals to patent a very effective epilepsy drug because there are elements that can be patented alongside cbd oil, which has never needed a patent and also can't be patented by itself. Many think this is sneaky and deceptive. Plus, the cost for a year's worth of EPIDIOLEX is roughly 32K. Whereas, a 12 month supply of highly effective CBD OIL is roughly 2k for the same treatment. Is this just the beginning of BIG PHARMA taking elements of a plant that's not able to be patented and combining them with synthetics, which then allow for a patent? Time will tell.........We broadcast live weekly on Facebook. Join us in our live broadcast and we look forward to trying something we’ve never seen people do before - we are going to ask our fans to ask questions via live video each week. If you want to join us in our broadcast, send us a message during the broadcast and attach your email address. We will include you in our live broadcast and allow you to ask questions of the host, or the guest. You can do this from your mobile phone, desktop computer, tablet, watch or whatever you choose to use. We’re excited to see how this experiment turns out. Please don’t get naked during the live feed - we don’t want to get banned (or threatened by your boyfriend).NOTE: If you like what we’re doing and want to help us, please click the “subscribe” button here on Youtube. Also, click the little "bell" icon so you get notifications from Youtube that we've uploaded new content. Tell your friends about us, so we can continue to share what we're doing with more people and expand our podcast to more like-minded individuals. More importantly, we also want you to know that this content will be available to consume on iTunes as an audio podcast, on Facebook as a video podcast and other places such as Soundcloud and Alexa voice. Join us on this journey, ask us lots of questions, tell your friends about it, suggest new guests, let us know if you’d like to become a sponsor, etc etc etc. Much love from the “MELLOW RIOT” team. We love what we're doing and the biggest help from you would be a simple "follow", "like", or even "share".INSTAGRAM: https://www.instagram.com/mellowriotp...FACEBOOK: https://www.facebook.com/mellowriotpo... TWITTER: https://www.twitter.com/mellowriot1SPONSORS:****FAST AND FRIENDLY CANNABIS DELIVERY****: https://www.fastandfriendly.us(The only cannabis delivery service to cover all of Southern California. Use promo code “MELLOWRIOT” to save 15% off of your first delivery in the shopping cart. Or, mention “MELLOW RIOT” when placing your first order to receive a $40 first time patient gift. The normal “FTP” gift is $20.)****GROOVE CRUISE****: https://www.groovecruise.com (Use “MELLOW RIOT” as a promo code to save $50 on the largest floating dance music party in the world.)****NUGG****: https://www.getnugg.com/invited/mello...(NUGG is the cannabis industry’s only full service shopping experience. Find cannabis in any state where it’s legal. Use the link above to save $20 off of your first order.)****COINBASE****: https://www.coinbase.com/join/5a2979a...(The world’s most secure way to buy and sell Bitcoin, Ethereum and Litecoin. Use the link above to get $10 in extra Bitcoin when you buy $100 or more.)****JOJO ELECTRO****: https://www.jojoelectro.com(The world's largest website dedicated entirely to dance music merchandise. The products only relate to techno, house, trance, dubstep, breaks and drum n' bass. Feel free to use "MELLOW RIOT" as a promo code to save 15% on anything in your shopping cart.)
In this episode #8 of the MELLOW RIOT PODCAST, the host Mike Mattarocci does a solo podcast as a trial run for more to come in the future, potentially. There are several articles reviewed in this VLOG. The first one was regarding doctors who are just now starting to feel comfortable recommending marijuana, but only for issues with nausea and appetite. They claim to not have enough research to direct people to cannabis for all of it's other amazing cancer fighting benefits - maybe big pharma is still breathing down their necks too heavily?The second article detailed how 60+ holistic doctors have all "committed suicide" in the last 2 years. Strangely, they all have 2-3 similar traits in common - they all prescribe either Rick Simpson Oil to their patients, or they recommend GcMaf, which is a very effective (and controversial) tool that battles cancer and many other diseases.The final commentary came from an article discussing the new patented drug EPIDIOLEX, which has cbd oil in it, as well as trace elements of a synthetic drug. This enables GW Pharmaceuticals to patent a very effective epilepsy drug because there are elements that can be patented alongside cbd oil, which has never needed a patent and also can't be patented by itself. Many think this is sneaky and deceptive. Plus, the cost for a year's worth of EPIDIOLEX is roughly 32K. Whereas, a 12 month supply of highly effective CBD OIL is roughly 2k for the same treatment. Is this just the beginning of BIG PHARMA taking elements of a plant that's not able to be patented and combining them with synthetics, which then allow for a patent? Time will tell.........We broadcast live weekly on Facebook. Join us in our live broadcast and we look forward to trying something we’ve never seen people do before - we are going to ask our fans to ask questions via live video each week. If you want to join us in our broadcast, send us a message during the broadcast and attach your email address. We will include you in our live broadcast and allow you to ask questions of the host, or the guest. You can do this from your mobile phone, desktop computer, tablet, watch or whatever you choose to use. We’re excited to see how this experiment turns out. Please don’t get naked during the live feed - we don’t want to get banned (or threatened by your boyfriend).NOTE: If you like what we’re doing and want to help us, please click the “subscribe” button here on Youtube. Also, click the little "bell" icon so you get notifications from Youtube that we've uploaded new content. Tell your friends about us, so we can continue to share what we're doing with more people and expand our podcast to more like-minded individuals. More importantly, we also want you to know that this content will be available to consume on iTunes as an audio podcast, on Facebook as a video podcast and other places such as Soundcloud and Alexa voice. Join us on this journey, ask us lots of questions, tell your friends about it, suggest new guests, let us know if you’d like to become a sponsor, etc etc etc. Much love from the “MELLOW RIOT” team. We love what we're doing and the biggest help from you would be a simple "follow", "like", or even "share".INSTAGRAM: https://www.instagram.com/mellowriotp...FACEBOOK: https://www.facebook.com/mellowriotpo... TWITTER: https://www.twitter.com/mellowriot1SPONSORS:****FAST AND FRIENDLY CANNABIS DELIVERY****: https://www.fastandfriendly.us(The only cannabis delivery service to cover all of Southern California. Use promo code “MELLOWRIOT” to save 15% off of your first delivery in the shopping cart. Or, mention “MELLOW RIOT” when placing your first order to receive a $40 first time patient gift. The normal “FTP” gift is $20.)****GROOVE CRUISE****: https://www.groovecruise.com (Use “MELLOW RIOT” as a promo code to save $50 on the largest floating dance music party in the world.)****NUGG****: https://www.getnugg.com/invited/mello...(NUGG is the cannabis industry’s only full service shopping experience. Find cannabis in any state where it’s legal. Use the link above to save $20 off of your first order.)****COINBASE****: https://www.coinbase.com/join/5a2979a...(The world’s most secure way to buy and sell Bitcoin, Ethereum and Litecoin. Use the link above to get $10 in extra Bitcoin when you buy $100 or more.)****JOJO ELECTRO****: https://www.jojoelectro.com(The world's largest website dedicated entirely to dance music merchandise. The products only relate to techno, house, trance, dubstep, breaks and drum n' bass. Feel free to use "MELLOW RIOT" as a promo code to save 15% on anything in your shopping cart.)
In this episode of The Pink Fox Podcast, hosts Mark, Keo, and Ronin, along with friend of the family/special guest/ganjapreneur Ratchet Geezus aka Wan Deuce aka Phil, discuss Phil's recent movements, happenings (i.e., raids) in the DC pop-up scene, the first annual DC Canna Film Festival, the abject failure of MoviePass, Mission: Impossible – Fallout, Bad Boys vs. Bad Boys II, a brief history of Pink Fox, Avengers: Infinity War, Mark's Stash app experience, GW Pharmaceuticals, the imaginary difference between Sativa and Indica plants, political nonsense in Washington, DJ Khaled's ‘No Brainer', and other topics.
This week on "Money Talks," Chief Investment Officer Troy Harmon, CFA, CVA, is joined by Principal Jennifer Thomas, CFP®, and Managing Associate K.C. Smith, CFP®, to discuss consumer confidence and housing news, including new home sales and home prices across 20 major cities. They also discuss how trade tariffs have weighed on the week’s market action. K.C. and Jennifer discuss what happens with your financial plan and time horizons when you’re blindsided by a life event. The experts also answer listeners' questions on cosmetics and fragrances company Estee Lauder, estimating your Social Security benefits, whether or not we are in a housing bubble, and cannabinoid biopharmaceutical company GW Pharmaceuticals.
The "Money Talks" experts answer listeners questions on cosmetics and fragrances company Estee Lauder, estimating your Social Security benefits, if we are in a housing bubble, and cannabinoid biopharmaceutical company GW Pharmaceuticals.
Though currently littered with penny stocks, the landscape for investing in marijuana is improving. Shannon Jones analyzes the recent merger of Aurora Cannabis and MedReleaf, and the impending FDA approval for GW Pharmaceuticals. Plus, we discuss how professional athletes and owners are helping the case by becoming more vocal about marijuana as a device for pain management.
The Dude & Scotty Real Are Hanging Out And Waking & Baking And Getting Into A Serbian Involved In Marijuana Trafficking & Bribery With A State Trooper, How Much Goes Into A Bottle Of Fiji Water, GW Pharmaceuticals Is Releasing Their CBD Product: Epidiolex With FDA Apporval On Todays Episode Of Wake & Bake America
The Dude & Scotty Real Are Hanging Out And Waking & Baking And Getting Into A Serbian Involved In Marijuana Trafficking & Bribery With A State Trooper, How Much Goes Into A Bottle Of Fiji Water, GW Pharmaceuticals Is Releasing Their CBD Product: Epidiolex With FDA Apporval On Todays Episode Of Wake & Bake America
Today in FirstWord:
Today on Hempire our host Dr. Eileen Karpfinger is joined by Dr. Ethan Russo the Director of Research and Development at International Cannabis and Cannabinoids Institute. Dr. Russo's background is as a physician, board-certified in Neurology with Special Qualification in Child Neurology, but He has always held a strong interest in medicinal plants, which he gradually incorporated into his practice and research endeavors, with the aim to bring cannabis-based and other botanical agents back into the mainstream of medicine. After 20 years experience in clinical practice, Russo transitioned in 2003 into a full-time consultancy position with GW Pharmaceuticals, a British pharmaceutical company developing prescription pharmaceuticals from the cannabis plant, which he held for 11 years. In 2015, Dr. Russo became Medical Director of PHYTECS, a company devoted to the research and development of medicines, supplements and lifestyle approaches to optimizing the function of the endocannabinoid system,the critical homeostatic regulatory mechanism of human physiology.
Today in FirstWord:
GW Pharma has cleared another hurdle in gaining FDA approval for its drug called Epidiolex, boosting stock value for the British drug maker.
Today in FirstWord:
Today in FirstWord:
In this week's podcast episode, Dr. Ethan Russo — one of our earliest and most esteemed guests — returns to the show to discuss his latest article, “Beyond Cannabis: Plants and the Endocannabinoid System.” Dr. Russo is a neurologist and psychopharmacology researcher, and is the former Senior Medical Advisor for GW Pharmaceuticals. He worked as a clinical neurologist in Missoula, Montana for 20 years, where much of his practice focused on the treatment of chronic pain. Today, Dr. Russo is one of the world's leading researchers in the field of cannabis terpenes and the endocannabinoid system. He has authored several books about cannabis, cannabinoids, pharmacology, and rare botanicals, and he has published over 30 articles covering neurology, pain management, cannabis, and ethno-botany. In this interview, Dr. Russo and Ganjapreneur podcast host Shango Los discuss how various foods — including black pepper, kava, the common carrot, and more — can actually help balance the cannabinoid levels in your body. For a full transcript: https://www.ganjapreneur.com/ethan-russo-endocannabinoid-nutrition/
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.
Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Alice Mead JD, Vice President of US Professionals Relations at GW Pharmaceuticals. They will hold a State of the Union discussion of Cannabidiol Laws in the United States.
Today in FirstWord:
When the acceptance of medical cannabis goes mainstream, the pharmaceuticals landscape will face the most significant disruption of its existence. Due to the federal classification of marijuana as a Schedule 1 controlled substance, researching possible medical uses for the plant has been difficult. However, this has not stopped some companies from conducting their own research and clinical trials of cannabis medicines. Our latest podcast interview features Dr. Ethan Russo, formerly Senior Medical Advisor to GW Pharmaceuticals, who participated in three clinical trials of the drug Sativex. Dr. Russo recently left GW Pharmaceuticals and can now speak publicly for the first time about his research: up until now, he could only be heard at expensive, exclusive conferences. He is now Medical Director at Phytecs, a company specializing in the production of cannabis-based treatments related to the endocannabinoid system. Everything that contemporary cannabis healers talk about in relation to cannabis as medicine is based on Dr. Russo's published research, including the power of cannabis terpenes, the Entourage Effect, and Endocannabinoid Deficiency. In this interview, our host Shango Los asks Dr. Russo about Endocannabinoid Deficiency (ECD) and the potential for it to be treated by cannabis. All human beings have an endocannabinoid system, which, according to Russo, regulates nearly every aspect of physiology. Endocannabinoid Deficiency is just coming into general awareness now as a cause behind several conditions including Migraines, Fibromyalgia, Irritable Bowel Syndrome, Phantom Limb Pain, Infantile colic, Glaucoma, PTSD, Bipolar disease and others. If cannabis becomes accepted by the mainstream medical community as a treatment for ECD and its associated conditions, the implications for the pharmaceuticals market would be staggering to say the least. Listen to the podcast or read the transcript below to learn about the science behind ECD and how cannabis can be used as a treatment. For a full transcript: https://www.ganjapreneur.com/ethan-russo-endocannabinoid-deficiency-medical-cannabis/
Today in FirstWord:
Today in FirstWord:
Today in FirstWord:
Hunter is the associate director of cannabinoid research at Canopy Growth Corporation, the largest cannabis producer in the world. Canopy Growth Corporation is a world-leading diversified cannabis company. They operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. Previously, Hunter was a global project manager at GW Pharmaceuticals and established its US clinical team. There, Land authored Dravet syndrome, LGS, and multiple-sclerosis protocols and managed the clinical development of the FDA-approved CBD Epidiolex. He speaks at cannabinoid and scientific conferences and collaborates with cannabinoid, neurology, and epilepsy experts, focusing on applications of cannabinoid formulations and their application across a variety of conditions. The land is a co-founder of the Cannabinoid Education Working Group and a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology.
The largest cannabis producer in the world with Hunter Land. Hunter is the associate director of cannabinoid research at Canopy Growth Corporation, the largest cannabis producer in the world. Canopy Growth Corporation is a world-leading diversified cannabis company. They operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. Previously, Hunter was a global project manager at GW Pharmaceuticals and established its US clinical team. There, Land authored Dravet syndrome, LGS, and multiple-sclerosis protocols and managed the clinical development of the FDA-approved CBD Epidiolex. He speaks at cannabinoid and scientific conferences and collaborates with cannabinoid, neurology, and epilepsy experts, focusing on applications of cannabinoid formulations and their application across a variety of conditions. The land is a co-founder of the Cannabinoid Education Working Group and a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology.
The largest cannabis producer in the world part 2 with Hunter Land. Hunter is the associate director of cannabinoid research at Canopy Growth Corporation, the largest cannabis producer in the world. Canopy Growth Corporation is a world-leading diversified cannabis company. They operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. Previously, Hunter was a global project manager at GW Pharmaceuticals and established its US clinical team. There, Land authored Dravet syndrome, LGS, and multiple-sclerosis protocols and managed the clinical development of the FDA-approved CBD Epidiolex. He speaks at cannabinoid and scientific conferences and collaborates with cannabinoid, neurology, and epilepsy experts, focusing on applications of cannabinoid formulations and their application across a variety of conditions. The land is a co-founder of the Cannabinoid Education Working Group and a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology.
© 2020-2025 Ivy Podcast Discovery LLC
